Clemson University

TigerPrints
All Dissertations

Dissertations

August 2014

Translating Knowledge of Autism Spectrum
Disorders to Action Through Tool Development
and Exploration
Rebecca A. Garcia
Clemson University, ragarci@clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Recommended Citation
Garcia, Rebecca A., "Translating Knowledge of Autism Spectrum Disorders to Action Through Tool Development and Exploration"
(2014). All Dissertations. 2405.
https://tigerprints.clemson.edu/all_dissertations/2405

This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

TRANSLATING KNOWLEDGE OF AUTISM SPECTRUM DISORDERS
TO ACTION THROUGH DISCOVERY AND EXPLORATION

A Thesis
Presented to
the Graduate School of
Clemson University

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Healthcare Genetics

by
Rebecca Ashmore Garcia
August 2014

Accepted by:
Dr. Julia Eggert, Committee Chair
Dr. Margaret A. Wetsel
Dr. D. Matthew Boyer
Dr. Alex Feltus
Dr. Brent Satterfield

ABSTRACT

Translational processes are needed to move research development, methods, and
techniques into clinical application. The knowledge to action framework organizes this
bench to bedside process through three phases including: research, translation, and
institutionalization without being specific to one disease or condition. The overall goal of
this research is to bridge gaps in the translational process from assay development to
disease detection through a mixed methods approach. A literature review identifies gaps
associated with intestinal permeability and autism spectrum disorders. Mining social
media related to autism and GI symptoms captures self-reported or observed data,
identifies patterns and themes within the data, and works to translate that knowledge into
healthcare applications. Development of novel tests can then examine relationships
between zonulin levels, haptoglobin genotype, and autism spectrum disorders, and
propose a paradigm shift in the use of proteomics and genomic diagnostic testing from
clinical diagnosis to pre-symptomatic testing. Although results from this study do not
find statistically significant relationships between zonulin and autism spectrum disorders,
they do suggest clinical significance and the need to conduct larger studies. The
discovery presents a novel approach for measuring intestinal permeability. Qualitative
and quantitative methods collaboratively point toward implementation of molecular and
data mining techniques in the development and evaluation of early diagnostic tests and
interventions. Equally, the two methods working together drive the field forward in
design and development to strengthen the outcomes.
Keywords: autism, zonulin, Radian6, haptoglobin, social media
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ABBREVIATIONS
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ALT
ARDS
AST
BBB
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NP
NS1
PAR2
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PPI-3
Pre-HP2
PRNT
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RNA
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STAT3
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WHO
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Non-structural protein 1 antibody
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CHAPTER I
INTRODUCTION
Early diagnostics make up the engine core that thrusts public and private research
through the translational process after discovery and development into clinical
application. Qualitative and quantitative methods are equally important in driving
research design toward conclusive experiences and evidence of disease states to
strengthen research outcomes.
Exposure to bacteria can occur at any time from conception to adulthood. Even
though childhood exposures may not be pathogenic, they may contribute to activation of
disease pathways. For example, zonulin is a protein that regulates the epithelial
permeability allowing macromolecules to pass into the blood stream (Tripathi et al.,
2009; Wang, Uzzau, Goldblum, & Fasano, 2000). Normally this process assists in
epithelial barrier protection from invading pathogens; however, the constitutive action of
zonulin increasing epithelial permeability can also result in molecules passing through
the barrier to initiate immune response and disease development (Drago et al., 2006;
Duerksen, Wilhelm-Boyles, Veitch, Kryszak, & Parry, 2010). Studies have identified
zonulin’s specific roles in intestinal and blood brain barrier permeability (Cipriani et al.,
2011; Diaz-Coranguez et al., 2013; Duerksen et al., 2010; Fasano et al., 2000; Lu et al.,
2000; Wang et al., 2000). The type of permeability suggests zonulin may play a role in
the pathological development of autism spectrum disorder (ASD) and related symptoms.
ASD affects 1 in 68 children in the United States (U.S.) with no known cause or
diagnostic test (Centers for Disease Control and Prevention [CDC], 2014). Interventions
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for autism typically involve multiple levels of trial and error using medication,
supplements, and an array of therapies with an annual expected lifetime cost of care at
$2.4 million per individual (Buescher, Cidav, Knapp, & Mandell, 2014).
Using the Center for Disease Control and Prevention’s (CDC) National Center for
Chronic Disease Prevention and Health Promotion (NCCDPHP) ‘Knowledge to Action’
framework, this dissertation participates in discovery through practice (Wilson et al.,
2011). The overall goal of this dissertation is to determine if it is possible to bridge gaps
in the translational process from assay development to disease detection through a mixed
methods approach.
Knowledge to Action Framework
The Knowledge to Action (K2A) framework used for this research project was
created by the CDC to organize the processes from bench to bedside through three phases
including research, translation, and institutionalization without being specific to one
disease or condition (Wilson et al., 2011). See Fig 1.1.

2

Figure 1.1
NCCDPHP Knowledge to Action Framework for Public Health

Figure 1.1 NCCDPHP Knowledge to Action Framework for Public Health. The figure
illustrates the three phases of the NCCDPHP K2A framework used with permission from
Wilson et al., 2011.
In this framework, each phase is made up of multiple components. For the purpose of this
dissertation, the definitions used by the CDC’s NCCDPHP K2A framework are
embraced. The research phases reflected in the subsequent chapters are the focus of this
dissertation project (Wilson et al., 2011).
The term ‘research’ refers to the first phase within the K2A framework and
includes discovery, efficacy, effectiveness, and research supporting structures (Wilson et
al., 2011). These guide the process of this dissertation research. Discovery encompasses
epidemiological, behavioral, and biomedical studies (Wilson & Fridinger, 2008).
Discovery is also comprised of initial ideas and thoughts that lead from synthesis of
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literature to development of a research plan. Discovery entails investigations of literature,
data, observations, and experiences. The discovery phase explores the literature to
establish a background and path moving forward. Discovery studies provide proof-ofconcept in order to acquire a larger research support network of organizations, scientists,
sample sizes, and funding. Efficacy and effectiveness intertwines with discovery to
explore where present interventions and testing fails or excels (Wilson & Fridinger,
2008). Efficacy refers to formative research, where attitudes, beliefs, and experiences can
be explored and incorporated into development of diagnostic tests and interventions
(Wilson & Fridinger, 2008). Efficacy allows the voice of the stakeholders to be
incorporated into the research model (Wilson & Fridinger, 2008). Results from these
initial experiments provide evidence to gather support from multiple disciplines and
investors to launch a full investigation that will either lead to the decision to translate or
continue with more discovery studies.
The K2A framework recognizes the need to incorporate all disciplines in the
translational process in order to put knowledge into action (Wilson et al., 2011). Part of
this translation includes measuring the gap between what is found in guidelines, the
literature, and to practice (Kitson & Straus, 2010). Chapter II provides a review of the
literature surrounding epithelial permeability, zonulin, and ASD. The review identifies a
gap in the literature in studies associating intestinal permeability with ASD and serum
zonulin levels in ASD individuals (D’Eufemia et al., 1996; De Magistris et al., 2010).
When gaps provide useful and relevant knowledge, exploring these gaps through
templates and tools can identify needs, gather resources, evaluate knowledge, discern

4

good from bad, and make information available to others (Turnbull et al., 2010). Social
media data mining provides this capability when focused on a specific disease or list of
symptoms. Chapter III is a discovery and efficacy study that looks for patterns among
people with ASD and gastrointestinal (GI) symptoms in social media data. The social
media research is part of discovery through collection of observations and experiences
and it is an efficacy study through its compilation of attitudes and beliefs of the
participants. Chapter IV follows with a discovery and efficacy study that measures
zonulin levels and haptoglobin genotype of ASD individuals, newborns, and healthy
controls to determine if zonulin can effectively detect the presence of ASD as an early
diagnostic test. Effectiveness research expands the optimal discovery and efficacy studies
to the translational phase through clinical trials and application (Wilson & Fridinger,
2008).
The clinical trials process follows a set of guidelines to ensure that a drug,
medical device, or therapy works efficiently and effectively without harming patients.
Each country has its own regulations that must be met before a product can pass this
stage and be sold to consumers. Clinical trials focus on reproducibility of efficacy and
effectiveness studies, and add double blind studies to eliminate possible researcher bias to
the outcome (Hróbjartsson et al., 2013). Repetition is necessary because the response in
humans may be different from those recorded from in vitro studies. Communication
between stakeholders is pertinent at this point to identify the needs and risks of
implementing scientific research into clinical practice (Droms, Ferguson, & Giuliano,
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2014). Stakeholders might include parents, caregivers, individuals with ASD, insurance
companies, clinicians, organizations, government agencies, or education sources.
Once the first phase of research is ended, the second phase of translation begins.
The K2A framework delineates translation as: decisions to translate, knowledge into
products, dissemination, engagement, decisions to adopt, practice, and translation
supporting structures (Wilson & Fridinger, 2008; Wilson et al., 2011). Translation is the
process by which an application is moved from the development phase into use in a
clinical setting. The process may include extensive validation procedures that confirm the
specificity and sensitivity of the test, as well as correlation studies with samples that have
been previously tested by a validated testing method. In many cases there is movement
between phases based on need to revisit the experimental processes related to the need to
refine and improve methods as a result of unexpected consequences of implementation,
advances in technology, environmental changes, or knowledge of genetic factors.
Research Phase of Zonulin Testing
The most common type of research in healthcare is quantitative research;
however, qualitative research is also important in understanding the patient experience,
assessment, diagnosis, and treatment. The early physicians, such as Hippocrates (460
B.C. -377B.C.), used observations and taste to determine disease states with a record of
their findings in journals (Medvei, 1993). Visual observations continued to be the
primary source of health assessment for diabetes until the first quantitative test was
developed in 1841 by Carl Trommer; followed by the more well-known urine sugar test
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developed by Hermann Fehling in 1848 (Medvei, 1993). As technology advanced and
more tests were developed, quantitative research became embedded in healthcare.
Today, researchers question whether one type of research is enough to provide
quality of care. Stuart and Wiles’ (1997) comparisons of questionnaires and interviews
suggest that use of only one type of research does not assess the complete understanding
of information, and it provides misleading information when used alone. The lack of
reproducibility between questionnaire and interview responses was significant (p<0.008),
indicating a lack of information about patient needs, beliefs, and experiences necessary to
facilitate self-management (Stuart & Wiles, 1997). Zhang and Creswell (2013) identify
outcomes of mixed methods in convergence, complementarity, development, initiation,
and expansion; whereas, the use of only quantitative methods fail to capture perspectives
from broad, complex groups. Both quantitative and qualitative research is needed to
develop and implement successful interventions and treatments. This dissertation uses
both qualitative and quantitative research to provide a more complete view of the
relationship between GI symptoms and ASD.
Quantitative and qualitative research looks at people and disease to identify a
problem and develop a research plan to test a hypothesis. In the field of healthcare,
stakeholders represent individuals and families affected by the same disease, those
experiencing similar symptoms, those going through similar therapies, healthcare
professionals, drugs, diseases, new technologies, or equipment. The stakeholders
involved in this dissertation research include individuals with ASD, caregivers or family
members, healthcare professionals, and private and public organizations. Each of these
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stakeholders may be affected or represented in the data collected from social media
outlets. The stakeholders are not always involved in the research groups, but they may be
indirectly affected by the research outcomes. Differences can be seen in the methodology,
data collection, and analysis of these groups. The term ‘quality’ has been recently defined
in healthcare as “the degree to which policies, programs, services, and research for the
population increase desired health outcomes and conditions in which the population can
be healthy” (Honore et al., 2012, p.739). Table 1.1 provides a list of common and
healthcare definitions for quality and quantity
Table 1.1
Quality verses Quantity Definitions

Common
Definitions
character
capacity
vividness of hue
degree of
excellence
Superiority
acquired skill
a distinguishing
attribute
social status

role

feature
Amount, estimate,

Quality
Medical Definitions
Accessibility and familiarity (Lee et al., 2013)
Test results (Lee et al., 2013)
Evidence- based practice (Lee et al., 2013)
cost effectiveness and service delivery (Lee et al., 2013)
A management process, set of tools, and techniques used to meet
healthcare needs (Riley et al., 2010)
how a group or person accepts rules, codes, laws, or conventions
(Berger, 2013)
provides details of behavior, routines, needs, and personality
characteristics (Madrigal & McClain, 2012)
examines patterns and relationships in the data to develop and test
hypotheses to generate theory or develop theory to explain data
(Morse & Field, 1995)
Effectiveness, access and timeliness, capacity, safety, patient
centeredness, and equity measurements (Committee on Quality of
Health Care in America, Institute of Medicine, 2001)
reaching a desired health outcome (Brilli et al., 2014)
Quantity
theory based, structured, systematic, planned, objective, logical, and
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or number
dependent on scientific thought (Berger, 2013)
Table 1.1 Quality and Quantity Definitions. The definitions for both terms above are
taken from Berger, 2013; Brilli et al., 2014; Committee on Quality of Health Care in
America, Institute of Medicine, 2001; Lee et al., 2013; Madrigal & McClain, 2012;
Morse & Field, 1995; Riley et al., 2010.
The combination of qualitative and quantitative measures increases the strength of
the findings and moves science forward through the K2A framework to the translation
phase. To begin the testing process, only quantitative research requires the formation of a
research plan through the identification of a problem and development of a testable
hypothesis. The strength of qualitative research can be found in description of the
problem and understanding how the intervention or research plan will work. Models and
diagrams can assist in conceptualization of the problem. These can be generated from
qualitative or quantitative software programs. In qualitative research, the hypothesis may
not be formed until data has been examined, at such point the hypothesis or research
questions may be edited. Patterns and relationships in qualitative data can be used to
develop and test hypotheses and to develop theories (Heyvaert, Maes, & Onghena, 2013;
Morse & Field, 1995).
Qualitative research is designed around a set of open ended research questions, so
the researcher can capture the viewpoint and context of the data being collected. Context
is important to qualitative research because it holds the meaning of the data. Questions
may differ depending on the design type, but they focus on understanding a single
concept, discussing the results, and incorporating new-understandings and ethical,
appropriate use of tests (Creswell, Hanson, Clark Plano, & Morales, 2007; Fetters, Curry,
& Creswell, 2013). Qualitative research has multiple design types such as narrative
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research, case study, grounded theory, phenomenology, and action research (Glesne,
2010). More than one design type can be used in an experiment or it can be mixed with
quantitative methods (Fetters et al., 2013; Palinkas et al., 2013).
Limitations and questions exist when exploring the use of mixed methods
research (Palinkas et al., 2013). The complexity of the data makes it difficult to analyze.
One example is that text and behaviors may have multiple meanings within the same
population; even more intensified across cultures and countries. Many times the question
arises “is the research beneficial; is it a worthwhile cause?” Bendassolli (2013) discusses
problems of induction of qualitative research explaining that in many circumstances
adequate information does not exist to formulate a theory and therefore nothing can be
tested. In addition, excessive amounts of data can overwhelm the analytical process;
therefore, researchers need to know how to manage and analyze large data sets.
Automation has sought to resolve analysis problems of large data sets in multiple
forms of research. Reliance on automation in qualitative data could lead to loss of context
or meaning of the data; therefore, automation should be viewed as a tool to help the
analyst interpret the data (Angus, Rintel, & Wiles, 2013). Another limitation shared
between qualitative and quantitative research is researcher bias. Berger (2013) explains
that when a person believes something should be done, he/she becomes selective and
neglects fully informative data. Berger (2013) associates the term quality with evaluation,
judgment, and taste. In qualitative research, this is also seen in data collected due to a
person’s motivation or personal interests in the research outcome.
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Motivation and involvement by researchers and participants can also be beneficial
in qualitative research (Barakat et al., 2013). Since qualitative research attempts to
capture the context of the data, it can be very powerful and useful in describing the
beliefs, desires, struggles, motivations, and responses to intervention of some groups
(Nicolaidis et al., 2011). For example, individuals who are diagnosed with ASD often do
not have a voice in research methodologies and designs. The autistic community has
been compared to voices of lesbian, gay, bisexual, transgendered, deaf individuals as they
represent individuals with a unique phenotype that is not shared by the rest of their
families (Nicolaidis et al., 2011). Qualitative research can capture the voices of these
minority groups without losing their passion and motivation to identification as a number.
By listening to the voices of those with ASD and their families, researchers can
incorporate their concerns and ideas into interventions and technologies (Nicolaidis et al.,
2011; Rowe & Nevin, 2013).
Ethically speaking the inclusion of all stakeholder points-of-view is vital in
developing technologies and/or resources that are both utilitarian and non-maleficent.
Although quantitative research is assuming more non-invasive methods of collection, it
does not maintain individual autonomy. In order to protect the anonymity of human
subjects, all forms of research removes the identity of a person. The representation of
autonomy and preservation of context in qualitative research may ultimately be its demise
in protecting individuals or organizations. For example, a simple search or publication of
reported data or phrases may inadvertently identify an individual, group, or organization.
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Much detail in protection of human subjects and de-identification of data must take place
in the development of both research methods.
The role of qualitative research in healthcare intervention is important and as a
result guidelines and checklists have been created to provide a framework for
development. In 2000, the British Medical Research Council (MRC) recognized that
qualitative research could provide beneficial information for complex medical
interventions (Medical Research Council, 2000). The MRC published guidelines in 2000
that proposed using qualitative research to identify mechanisms and determine
effectiveness of interventions. These guidelines were updated in 2008 to focus on
qualitative properties that maintain context of information (Medical Research Council,
2008). These guidelines help in development of a framework to approach qualitative
research. Using these guidelines, this research incorporates them into the K2A
framework.
Exploring Social Media
The research phase of this project is divided into two parts based on utilization of
qualitative and quantitative methods to reach the overall goal of developing early
diagnostic tests for ASD based on gastrointestinal symptoms. The qualitative portion of
this research compares relationships between known physiological effects of zonulin and
symptoms of ASD recorded through social media and phenotypic assessment. This study
utilizes three months of public information to identify symptoms of ASD described
through social media. Radian6 software designed to assist with queries of social media
was used to collect the data. The ASD social media data was analyzed to identify
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symptoms unique to autism implicating epithelial permeability physiological pathways
related to increased risk of developing ASD. The qualitative portion of this research
project focused on the following aims:
AIM 1: To determine themes and patterns of ASD from social media
AIM 2: To understand the impact of social media on self-management of ASD with comorbid intestinal manifestations.
AIM 3: To identify common symptoms and/or thematic elements used through social
media
The research seeks to answer the following research questions:
1. What symptoms are expressed in recorded social media data related to ASDs?
2. What are the themes related to ASD from social media?
3. What are the facilitators and barriers of social media use in relation to ASD?
Zonulin Pathway to Autism Spectrum Disorders
Although the pathology between ASD and GI symptoms has not been clearly
defined, the Autism Research Institute (2013) reported that up to 70% of ASD individuals
suffer with GI issues. The most commonly reported symptoms of ASD are social
impairment, communication difficulties, and repetitive and stereotyped behaviors.
Additionally, symptoms of stomach pain, diarrhea, constipation, acid reflux, vomiting,
bloating, and food allergies have been reported (Chaidez, Hansen, & Hertz-Picciotto,
2014; Chandler et al., 2013; Mazefsky, Schreiber, Olino, & Minshew, 2013; National
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Institute of Mental Health, 2011; Peters et al., 2014). Currently no diagnostic test is
available to detect the presence or severity of ASD.
Zonulin, pre-haptoglobin (HP) 2, is a complex protein structure that regulates
epithelial tight junctions, allowing macromolecules to pass across cell membranes into
the blood stream causing altered immune responses (Wang et al., 2000; Tripathi et al.,
2009). Although the relationship between ASD and the immune system is unclear, studies
have identified associations between ASD and intestinal permeability (D’Eufemia et al.,
1996; De Magistris et al., 2010), and between ASD males and HP genotypes (Aposhian,
Zakharyan, Chowdhury, & Avram, 2006). However, no studies reported in the literature
have directly measured zonulin levels in ASD populations. Therefore, there is a need to
determine the role of zonulin in ASD.
The long term goal for this research is to provide a diagnostic assay that correlates
the ASD diagnostic scale with different grades of GI severity. Based on pathophysiology
of rising zonulin levels, the overall objective is to determine if there is a relationship
between increasing or decreasing zonulin levels and ASD. The central hypothesis is that
increases in zonulin concentrations in plasma are directly associated with ASD severity
and that HP2-2 genotypes place an individual at a higher risk for developing ASD. The
basis for this hypothesis is there is a correlation between intestinal permeability in
individuals diagnosed with ASD, severity of ASD and symptoms of severe GI diseases
(Adams, Johansen, Powell, Quig, & Rubin, 2011). Zonulin levels and haptoglobin
genotypes will be determined from banked plasma and genomic deoxyribonucleic acid
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(DNA) samples retrieved from the Greenwood Genetic Center. In order to test this
hypothesis and accomplish the objectives, the following specific aims are proposed:
Aim 4: Determine if zonulin levels in plasma obtained from individuals diagnosed
with an ASD (Group 1) or newborns (Group 2) are different from zonulin levels in
controls of healthy individuals matched by age and/ or gender (Group 3). Zonulin
levels will be quantified using an enzyme-linked immunosorbent assay. The working
hypothesis is that increased zonulin levels in plasma are directly associated with the
presence and severity of ASD.
Aim 5: Examine relationships between HP2 genotypes and increased zonulin levels
in individuals with ASD (Group 1) or newborns (Group 2) compared to healthy
controls matched by age and/or gender (Group 3). HP genotype will be determined
using real time PCR. It is postulated that HP2-2 genotypes and zonulin will be increased
in individuals with ASD.
Aim 6: Determine if zonulin levels are good predictors between ASD and healthy
control groups. It is postulated that increased zonulin levels will predict the presence of
ASDs.
The proposed research focused on identifying the role of zonulin or HP genotype in
determining risk and severity of ASD. The results from this study will provide
information for the development of a novel, quantifiable, diagnostic test to determine risk
and/or severity of ASD. Additionally, the results will provide new mechanisms of interest
for future preventive or therapeutic interventions.
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Summary
This chapter introduces the K2A framework and illustrates how each subsequent
chapter brings this research from discovery to the translational phase. Chapter II
synthesizes the literature in discovery of what is known and the gaps surrounding
epithelial permeability related to zonulin and ASD. The information gained from the
literature search identified a lack of zonulin testing among ASD individuals even though
there were numerous publications which associated intestinal permeability and
gastrointestinal symptoms with ASD. In order to fill this gap in literature, discovery and
efficacy studies were planned and tested. Chapter III explores social media used to
capture experiences, attitudes, and beliefs of individuals affected directly or indirectly by
ASD and GI symptoms. The patterns and themes collected from mining social media
supported future exploration. Chapter IV continued the discovery and efficacy studies by
measure zonulin levels and haptoglobin genotype in individuals with ASD, newborns,
and healthy controls.

16

REFERENCES
Adams, J.B., Johansen, L.J., Powell, L.D., Quig, D., & Rubin, R.A. (2011).
Gastrointestinal flora and gastrointestinal status in children with autism—
comparisons to typical children and correlation with autism severity. BioMed
Central Gastroenterology, 11, 22. doi:10.1186/1471-230X-11-22
Angus, D., Rintel, S., & Wiles, J. (2013). Making sense of big text: a visual-first
approach for analysing text data using Leximancer and Discursis. International
Journal of Social Research Methodology, 16(3), 261-267.
Aposhian, H.V., Zakharyan, R.A., Chowdhury, U.K., & Avram, M.D. (2006). Search for
plasma protein biomarker for autism using differential in-gel electrophoresis.
Toxicological Sciences, 90(1-S), 23.
Autism Research Institute. (2013). Gastrointestinal Symptoms. Retrieved from
http://www.autism.com/index.php/gastrointestinal
Autism Speaks. (2012, March 28). New Research Finds Annual Cost of Autism Has
More Than Tripled to @126 Billion in the U.S. and Reached £34 Billion in the
U.K. Available from http://www.autismspeaks.org/about-us/pressreleases/annual-cost-of-autism-triples
Barakat, L. P., Patterson, C. A., Mondestin, V., Chavez, V., Austin, T., Robinson, M. R.,
... & Cohen, R. (2013). Initial development of a questionnaire evaluating
perceived benefits and barriers to pediatric clinical trials participation.
Contemporary clinical trials, 34(2), 218-226.

17

Bendassolli, P.F. (2013). Theory Building in Qualitative Research: Reconsidering the
Problem of Induction. Forum: Qualitative Social Research, 14(1). Available from
http://www.qualitative-research.net/index.php/fqs/article/view/1851/3497
Berger, A. (2013). Media and Communication Research Methods: An Introduction to
Qualitative and Quantitative Approaches (3rd ed.). Los Angeles: SAGE
Publications, Inc.
Brilli, R. J., Allen, S., & Davis, J. T. (2014). Revisiting the Quality Chasm. Pediatrics,
133(5), 763-765.
Buescher, A., Cidav, Z., Knapp, M., & Mandell, D. (2014). Costs of Autism Spectrum
Disorders in the United Kingdom and the United States. JAMA Pediatrics. Doi:
10.1001/jamapediatrics.2014.210
Centers for Disease Control and Prevention. (2014, March 28). Surveillance Summaries,
63(SS02), 1-21.
Chaidez, V., Hansen, R. L., & Hertz-Picciotto, I. (2014). Gastrointestinal problems in
children with autism, developmental delays or typical development. Journal of
autism and developmental disorders, 44(5), 1117-1127.
Chandler, S., Carcani-Rathwell, I., Charman, T., Pickles, A., Loucas, T., Meldrum, D., ...
& Baird, G. (2013). Parent-reported gastro-intestinal symptoms in children with
autism spectrum disorders. Journal of autism and developmental disorders,
43(12), 2737-2747.
Cipriani, S., Mencarelli, A., Chini, M.G., Distrutti, E., Renga, B., Bifulco, G., …
Fiorucci, S. (2011). The Bile Acid Receptor GPBAR-1 (TGR5) Modulates

18

Integrity of Intestinal Barrier and Immune Response to Experimental Colitis.
Public Library of Science One,6(10), e25637. Doi: 10.1371/journal.pone.0025637
Committee on Quality of Health Care in America, Institute of Medicine. (2001). Crossing
the quality chasm: a new health system for the 21st century. Washington, DC:
National Academy Press. Available from http://books.nap.edu/books
/0309072808/html/index.html
Creswell, J.W., Hanson, W.E., Clark Plano, V.L., & Morales, A. (2007). Qualitative
Research Designs: Selection and Implementation. The Counseling Psychologist,
35, 236. Doi: 10.1177/0011000006287390
De Magistris, L., Familiari, V., Pascotto, A., Sapone, A., Frolli, A., Iardino, P., …
Bravaccio, C. (2010). Alterations of the intestinal barrier in patients with autism
spectrum disorders and in their first-degree relatives. Journal of Pediatric
Gastroenterology and Nutrition, 51, 418-424.
D’Eufemia, P., Celli, M., Finocchiaro, R., Pacifico, L., Viozzi, L., Zaccagnini, M., …
Giardini, O. (1996). Abnormal intestinal permeability in children with autism.
Acta Paediatrica, 85(9), 1076-1079.
Diaz-Coranguez, M., Segovia, J., Lopez-Ornelas, A., Puerta-Guardo, H., Ludert, J.,
Chavez, B, … Gonzalez-Mariscal, L. (2013). Transmigration of Neural Stem
Cells across the Blood Brain Barrier Induced by Glioma Cells. Public Library of
Science One,8(4), e60655. Doi:10.1371/journal.pone.0060655
Drago, S., El Asmar, R., Di Pierro, M., Clemente, M.G., Tripathi, A., Sapone, A., …
Fasano, A. (2006). Gliadin, zonulin and gut permeability: Effects on celiac and

19

non-celiac intestinal mucosa and intestinal cell lines. Scandinavian Journal of
Gastroenterology, 41, 408-419.
Droms, C. M., Ferguson, M., & Giuliano, K. (2014). The Stakeholder Approach: A New
Perspective on Developing and Marketing Clinical Trials. Health marketing
quarterly, 31(1), 1-12.
Duerksen, D.R., Wilhelm-Boyles, C., Veitch, R., Kryszak, D., & Parry, D.M. (2010). A
Comparison of Antibody Testing, Permeability Testing, and Zonulin Levels with
Small-Bowel Biopsy in Celiac Disease Patients on a Gluten-Free Diet. Digestive
Diseases and Sciences, 55, 1026-1031.
Fasano, A., Not, T., Wang, W., Uzzau, S., Berti, I., Tommasini, A., & Goldblum, S.E.
(2000). Zonulin, a newly discovered modulator of intestinal permeability, and its
expression in coeliac disease. The Lancet, 355, 1518-1519.
Fetters, M. D., Curry, L. A., & Creswell, J. W. (2013). Achieving integration in mixed
methods designs—principles and practices. Health services research, 48(6pt2),
2134-2156.
Glesne, C. (2010). Becoming qualitative researcher: an introduction (4th Ed.). Boston:
Pearson.
Heyvaert, M., Maes, B., & Onghena, P. (2013). Mixed methods research synthesis:
definition, framework, and potential. Quality & Quantity, 47(2), 659-676.
Honore, P.A., Wright, D., Berwick, D.M., Clancy, C.M., Lee, P., Nowinski, J., & Koh,
H.K. (2011). Creating A Framework For Getting Quality Into The Public Health
System. Health Affairs, 30(4), 737-745. Doi: 10.1377/hlthaff.2011.0129

20

Hróbjartsson, A., Thomsen, A. S. S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I.,
... & Brorson, S. (2013). Observer bias in randomized clinical trials with
measurement scale outcomes: a systematic review of trials with both blinded and
nonblinded assessors. Canadian Medical Association Journal, cmaj-120744.
Kitson, A., & Straus, S.E. (2010). The knowledge-to-action cycle: identifying the gaps.
CMAJ, 182(2), E73-E77.
Lee, H., Vlaev, I., King, D., Mayer, E., Darzi, A., & Dolan, P. (2013). Subjective wellbeing and the measurement of quality in healthcare. Social Science & Medicine,
99, 27-34.
Lu, R., Wang, W., Uzzau, S., Vigorito, R., Zielke, H.R., & Fasano, A. (2000). Affinity
Purification and Partial Characterization of the Zonulin/Zonula Occludens Toxin
(Zot) Receptor from Human Brain. Journal of Neurochemistry, 74(1), 320-326.
Madrigal, D., & McClain, B. (2012). Strengths and Weaknesses of Quantitative and
Qualitative Research. UXMatters. Available from
http://www.uxmatters.com/mt/archives/2012 /09/strengths-and-weaknesses-ofquantitative-and-qualitative-research.php
Mazefsky, C. A., Schreiber, D. R., Olino, T. M., & Minshew, N. J. (2013). The
association between emotional and behavioral problems and gastrointestinal
symptoms among children with high-functioning autism. Autism,
1362361313485164.
Medical Research Council. (2000). Framework for development and evaluation RCTs for
complex interventions to improve health. London: Medical Research Council.

21

Medical Research Council. (2008). Developing and evaluating complex interventions:
New guidance. London: Medical Research Council. Available from
http://www.mrc.ac.uk/complexinterventionsguidance
Medvei, V.C. (1993). The History of Clinical Endocrinology. New York: The Parthenon
Publishing Group Inc.
Morse, J.M., & Field, P.A. (1995). Qualitative Research Methods for Health
Professionals (2nd ed.). London: Chapman & Hill.
Nicolaidis, C., Raymaker, D., McDonald, K., Dern, S., Ashkenazy, E., Boisclair, C.,
Robertson, S., & Baggs, A. (2011). Collaboration Strategies in Nontraditional
Community-Based Participatory Research Partnerships: Lessons From an
Academic-Community Partnership With Autism Self-Advocates. Progress in
Community Health Partnerships, 5(2), 143-150.
Palinkas, L. A., Horwitz, S. M., Green, C. A., Wisdom, J. P., Duan, N., & Hoagwood, K.
(2013). Purposeful sampling for qualitative data collection and analysis in mixed
method implementation research. Administration and Policy in Mental Health and
Mental Health Services Research, 1-12.
Peters, B., Williams, K. C., Gorrindo, P., Rosenberg, D., Lee, E. B., Levitt, P., &
Veenstra-VanderWeele, J. (2014). Rigid–Compulsive Behaviors are Associated
with Mixed Bowel Symptoms in Autism Spectrum Disorder. Journal of autism
and developmental disorders, 44(6), 1425-1432.

22

Riley, W.J., Moran, J.W., Corso, L.C., Beitsch, L.M., Bialek, R., & Cojsky, A. (2010).
Defining Quality Improvement in Public Health. Journal of Public Health
Management & Practice, 16(1), 5-7. Doi: 10.1097/PHH.0b013e3181bedb49
Rowe, G., & Nevin, H. (2013). Bringing ‘patient voice’into psychological formulations
of in‐patients with intellectual disabilities, autism spectrum disorder and severe
challenging behaviours: report of a service improvement pilot. British Journal of
Learning Disabilities.
Stuart, L., & Wiles, P.G. (1997). A comparison of qualitative and quantitative research
methods used to assess knowledge of foot care among people with diabetes.
Diabetic Medicine, 14(9), 785-791.
Tripathi, A., Lammers, K.M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza,
M.S., … Fasano, A. (2009). Identification of human zonulin, a physiological
modulator of tight junctions, as prehaptoglobin-2. Proceedings of the National
Academy of Sciences, 106 (39), 16799-16804.
Turnbull, A., Zuna, N., Hong, J.Y., Hu, X., Kyzar, K., Obremski, S., … Stowe, M.
(2010). Knowledge-to-action guides. Teaching Exceptional Children, 42(3), 4253.
U.S. Department of Health and Human Services, National Institutes of Mental Health.
(2011). A Parent’s Guide to Autism Spectrum Disorder (Publication No. 115511). Retrieved from http://www.nimh.nih.gov/health/publications/a-parent-sguide-to-autism-spectrum-disorder/parent-guide-to-autism.pdf

23

Wang, W., Uzzau, S., Goldblum, S.E., & Fasano, A. (2000). Human zonulin, a potential
modulator of intestinal tight junctions. Journal of Cell Sciences, 113, 4435-4440.
Wilson, K.M., Brady, T.J., Lesesne, C., on behalf of the NCCDPHP Work Group on
Translation. (2011). An organizing framework for translation in public health: the
Knowledge to Action Framework. Preventing Chronic Disease, 8(2), A46.
Available from http://www.cdc.gov/pcd/issues/2011/mar/10_0012.html
Wilson, K.M., & Fridinger, F. (2008). Focusing on Public Health: A Different Look at
Translating Research to Practice. Journal of Women’s Health, 17(2), 173-179.
Zhang, W., & Creswell, J. (2013). The use of" mixing" procedure of mixed methods in
health services research. Medical care, 51(8), e51-e57.

24

CHAPTER II
ZONULIN PATHWAY TO AUTISM SPECTRUM DISORDERS
Rebecca A. Garcia
Clemson University

Author Note
Rebecca A. Garcia, School of Nursing, Healthcare Genetics Doctoral Program, Clemson
University. This research was performed as part of the doctoral research requirements of
the Healthcare Genetics Doctoral Program.

Correspondence concerning this article should be addressed to Rebecca Garcia, Clemson
University, 528 Edwards Hall, Clemson, SC 29634.
Email: ragarci@clemson.edu
Phone: (864)421-3757

25

Abstract
Tight junctions are protein complexes regulated by zonulin. The modulation of the tight
junctions allows macromolecules to pass, causing a disruption in homeostatic
mechanisms that play important roles in the development of immunity and disease. This
paper will explain the physiological mechanisms and molecular pathways through which
zonulin is or could be associated with symptoms or disease especially Autism Spectrum
Disorders. The hypothesis is increased serum zonulin levels and comparisons of the
physiological effects of zonulin and phenotypic assessment data can be used to implicate
severity of disease states. Furthermore, a model of the zonulin pathway to disease is
presented.
Keywords: tight junctions, zonulin, prehaptoglobin2, autism, Autism Spectrum
Disorder
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Zonulin Pathway to Autism Spectrum Disorders
Tight junctions (TJ), or zonulae occludentes, are continuous intercellular spaces
between epithelial cells that are composed of more than 40 proteins (Anderson & Van
Itallie, 2009; Fasano, 2001). Presently these proteins consist of the occludins, claudins,
junctional adhesion molecules, and cytoplasmic plaque proteins necessary for structural
functions (Nusrat, Turner, & Madara, 2000). Specifically TJs have two main functions:
they serve as a barrier to protect against microorganisms by allowing only molecules with
radii less than 15Å or 3.5kDa to pass into the cell, and they transport fluids,
macromolecules, and leukocytes in and out of body compartments (Fasano, 2008;
Fasano, A., 2011; Tripathi et al, 2009). Zonulin has been identified as a 47-kDa protein
that regulates the opening and closing of TJs (Wang, Uzzau, Goldblum, & Fasano, 2000;
Tripathi et al., 2009). The modulation of TJs allows macromolecules to pass into the
bloodstream, thus playing an important role in the development of immunity and disease.
The purpose of this paper is to explain the physiological mechanisms and molecular
pathways through which zonulin regulates tight junctions. Furthermore, a model of the
zonulin pathway to disease will be presented.
The Zonulin Pathway
Fasano et al. (1991) identified zonulin occludens toxin (ZOT), an enterotoxin
produced by Vibrio cholerae, as a regulator of TJ. Diarrhea in patients testing negative
for cholera toxin raised suspicion that another toxin produced by Vibrio cholerae may be
present (Fasano et al., 1991). The results from the study by Fasano et al. (1991) indicated
that ZOT increased intestinal permeability by altering the structure of intercellular TJ,
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which allowed water and electrolytes to leak into the lumen of the small intestine
resulting in diarrhea. A follow-up study by Baudry, Fasano, Ketley, & Kaper (1992)
identified three ZOT genes CVD101, CVD108, and 395-N1. This study further defined
ZOT as a 44.8kDa protein responsible for abdominal cramps, malaise, vomiting,
headaches, and diarrhea. The zot gene was identified upstream of cholera toxin (ctx)
genes with its terminal codon overlapping the ctx promoter (Baudry et al., 1992). ZOT
binding was detected in jejunum and distal ileum, not the colon (Fasano, 2011; Fasano,
2008; Di Pierro et al, 2001). Affinity purified anti-ZOT antibodies tested on mammalian
tissue in ussing chambers identified zonulin as a eukaryotic homolog to ZOT (Wang et
al., 2000). In the same study, a comparison of adult and fetal intestinal tissue by microsequencing revealed that the N-terminal sequence of fetal zonulin
(MLQKAESGGVLVQPG) is 60% identical to adult zonulin (EVQLVESGGXL) (Wang
et al., 2000). The differences in the N-terminal sequences were believed to be due to fetal
development, which also explained why the adult form regulated paracellular
permeability while fetal forms regulated molecules between body compartments during
embryogenesis (Wang et al., 2000). Since its first discovery, zonulin has been associated
with several autoimmune diseases (Fasano, 2012).
Fasano (2011) connected zonulin and its associated diseases to chromosome 16
through two haptoglobin genes mapped to chromosome 16. A recent search in the
University of California, Santa Cruz genome browser (http://genome.ucsc.edu/) using the
human February 2009 (GRCh37/hg19) assembly identified the two genes as Haptoglobin
(HP) mapped to chr16:72,088,508-72,094,955 and Haptoglobin-related protein (HPR)
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mapped to chr16:72,097,125-72,111,145. Zonulin shows structural similarities to
chymotrypsin and serine proteases which provide functions of reversibility, secretability,
and presence in digestion, blood clotting, and complement (Fasano, 2011). The list of
diseases linked to chromosome 16 included celiac disease, type 1 diabetes, asthma,
multiple sclerosis, glioma, inflammation, and autism (Fasano, 2011; Swanwick, Larsen,
Banerjee-Basu, & Banerjee-Basu, 2011).
A review of the related literature as of July 2014 indicates a list of diseases that
are suggested to show association with between intestinal permeability and the zonulin
pathway. A search in Academic Search Complete using the terms “intestinal permeability
AND zonulin” yielded 68 articles. A brief review of the titles and abstracts excluded
articles discussing intestinal permeability without the mention of the zonulin or disease
association with genotypes of haptoglobin. Nineteen articles discussed a probable
association between disease and intestinal permeability via the zonulin pathway.
Table 2.1
Diseases Associated with Zonulin
Physiological
Category
Gastrointestinal
System

Respiratory
System

Nephrological
System

Disease
Celiac

Colitis
Crohn’s Disease
Acute Lung Injury
Acute Respiratory
Distress Syndrome
Asthma
Chronic Kidney
Disease

References
Duerksen, Wilhelm-Boyles, Veitch,
Kryszak, & Parry, 2010; Fasano et al., 2000;
Tripathi et al., 2009; Wang et al., 2000
Duerksen et al., 2010
Fasano , 2008
Matthay et al., 2003
Matthay et al., 2003
Fasano, 2011
Kelly et al., 2009
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Neurological
System
Endocrine System

Schizophrenia
Alzheimers
Multiple Sclerosis
Obesity

Paterson et al., 2007
Liu, Wang, Zhang, Wei, & Li, 2012
Fasano, 2011
Moreno-Navarrete et al., 2012; Zak-Gołąb et
al., 2013
Jayashree et al., 2014; Moreno-Navarrete et
al., 2012
Sapone et al., 2006; Watts et al., 2005
Pavon et al., 2006

Diabetes Mellitus
Type 2
Type 1 Diabetes
Systemic Lupus
Erythematosus
Infectious
HIV
Liu et al., 2012
Diseases
HCV
Fasano, 2011
Sepsis
Klaus et al., 2013
Cancers
Breast Cancer
Russo et al., 2013
Glioblastoma
Skardelly et al., 2009
Lung squamous
Fasano, 2011
carcinoma
Pancreatic carcinoma Fasano, 2011
Table 2.1 Diseases Associated with Zonulin.

Zonulin exists in two forms: an un-cleaved form known as pre-haptoglobin 2 (preHP2) that binds to proteinase activated receptor 2 (PAR2) and epidermal growth factor
receptor (EGFR), and a form cleaved by trypsin at Arg161 that seeks to bind hemoglobin
(Tripathi et al., 2009; Fasano, 2012). The initial studies indicated that the two different
forms of zonulin yield two different functions due to the folding of the protein, with only
the un-cleaved form affecting epithelial permeability (Fasano, 2012; Tripathi et al.,
2009). Current research suggests that both forms of zonulin affect permeability (Rittirsch
et al., 2013). Additional research is needed to determine if permeability resulting from
increased zonulin levels is due to tissue or model specific responses. Zonulin is heavily
concentrated in the endoplasmic reticulum (ER) and golgi (Drago et al., 2006). The uncleaved form of zonulin can be detected in human serum at a range of 80-208µg/mL
(Tripathi et al., 2009).
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Recent studies of micro-ribonucleic acid (miRNA) have shed light on
transcription of haptoglobin. The discovery of an acute-phase response regulatory
pathway shows that micro-RNA-18a can enhance interleukin 6 (IL-6) release from
monocytes and immune cells causing phosphorylation and dimerization of signal
transducer and activator of transcription 3 (STAT3) in the liver (Brock, Trenkmann, Gay,
Gay, Speich, & Huber, 2011; Gauldie, Richards, Harnish, Lansdorp, & Baumann, 1987;
Wegenka, Buschmann, Lutticken, Heinrich, & Horn, 1993). STAT3 homodimers then
move to the nucleus and bind to promoter regions of deoxyribonucleic acid (DNA) to
stimulate transcription of IL-6 target genes haptoglobin and fibrinogen (Brock et al.,
2011). Intracellular feedback loops maintain the expression of STAT3 for transcription
(Brock et al., 2011). The involvement of STAT3 in transcription of haptoglobin suggests
that mutations in STAT3 may lead to interruptions in the zonulin pathway and maybe
associated with other diseases and conditions. Research is needed to understand specific
factors related to translation of RNA to zonulin protein.
To better understand and develop associations with disease it is important to begin
with examining what triggers activation of the zonulin pathway. Activation of zonulin
occurs through exposure to gliadin, bacteria, and viruses (Drago et al., 2006; Fasano,
2012, Guttman & Finlay, 2009). Gliadin is one of two protein products of gluten. Gliadin
binds to chemokine (C-X-C motif) receptor 3 (CXCR3) which recruits an adapter protein
MyD88 increasing intestinal permeability and activating the release of zonulin (Lammers
et al., 2008). Zonulin interacts with different surface receptors to activate phospholipase
C, hydrolyzing phosphatidyl inositol into inositol 1,4,5-tris-phosphate (PPI-3) and
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diacylglycerol (DAG) (Fasano, 2001; Mowat, 2003; Brandtzaeg et al., 1989). DAG and
PPI-3 mediate protein kinase C through different mechanisms. DAG can directly bind to
protein kinase C, whereas PPI-3 causes the release of intracellular calcium leading to
protein kinase C mediation (Drago et al., 2006; Visser, Rozing, Sapone, Lammers, &
Fasano, 2009). In both cases, protein C mediation leads to polymerization of intracellular
actin filaments leading to the reorganization and restructure of the cytoskeleton and
epithelial barriers (Drago et al., 2006; Visser et al., 2009). Actin filaments function
mainly in cell growth and shape. When actin filaments reorganize they can form fiberlike cables to provide shape and purpose to nerve cells or they can form track-like
structures to transport molecules or microbial materials (Ivanov et al., 2010; Singh et al.,
2010).
The reorganization of actin filaments can be visualized using human Caco2 cells
and rat IEC6 cells. Caco2 cells from human colorectal adenocarcinoma in monolayers
provide a model for small intestine enterocytes and tight junctions. One study exposed
these two cell groups to gliadin to view the redistribution of proteins that make up the TJ
complex (Drago et al., 2006). It is the N-terminal sequence of pre-HP2 that shares a
common motif (GGVLVQPG) with the active ZOT fragment, binding to specific surface
receptors that activate signaling pathways (Fasano, 2008).
Another study found the N-terminal sequences of Zot/zonulin binding proteins
showed dose dependent binding in human brain, intestine, and heart tissues suggesting
disease association with increased zonulin levels in these systems (Lu, Wang, Uzzau,
Vigorito, Zielke, & Fasano, 2000). The serine protease characteristics and growth
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hormone-like structures of pre-HP2 induce protease-activated receptor 2 (PAR2)
dependent transactivation of epidermal growth factor receptor (EGFR) (Lammers et al.,
2008; Fasano, 2012). Six spatially conserved cysteine residues in the ß-chain of pre-HP2
form three intramolecular disulfide bonds which are involved in epidermal growth factor
activity. Concentrations of pre-HP2 ≥15 µg/mL are enough to activate EGFR (Tripathi et
al., 2009). Activation and mutations in EGFR have been associated with lung
adenocarcinoma, non-small cell lung carcinoma, breast cancers, colon cancers, and
response to radiation and drug therapies (Ellina et al., 2014; McCarty, 2014; Nechushtan
et al., 2014; Pan et al., 2014; Suda et al., 2014). Therefore, the association between
zonulin and EGFR suggests involvement with cancers and drug therapies (McCarty,
2014; Suda et al., 2014).
The other triggers of zonulin activation occur by the unique TJ modifications
caused by bacteria and viral pathogens (Guttman & Finlay, 2009). Figure 2.1 is a
representation published by Guttman and Finlay (2009) demonstrating how different
bacteria and viruses alter the TJ.
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Figure 2.1
Bacteria and Virus Alteration of Tight Junctions

Figure 2.1 Bacteria and Virus Alteration of Tight Junctions. The figure shows how
bacteria and viral pathogens alter the tight junctions (Guttman & Finlay, 2009).
The success of a bacteria or virus to penetrate the epithelial barrier or disassemble
the TJ results in infection and inflammatory response (Guttman & Finlay, 2009). The
attack on the epithelial barrier is two-sided. The lumen side is penetrated and altered
through exposure to pathogenic organisms and toxins while the mucosal side is exposed
to immune cell secretions of cytokines, proteases, and reactive oxygen species (Ivanov et
al., 2010). Enteric microorganisms induce luminal secretion of zonulin in the small
intestine and open the TJ (Fasano, 2008). Hydrostatic pressure gradients form, increasing
water secretions into the lumen which flush bacteria from the intestine (Fasano, 2001;
Fasano, 2008). These two mechanisms of zonulin activation provide a foundation to
explore development of symptoms and diagnosis of disease.
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Physiological System Involvement
Cell models, animal models, and human studies have identified physiologic
mechanisms of zonulin and their association with disease. A review of the literature
identifies four physiological systems and disease models that are disrupted due to
increased epithelial permeability: Gastrointestinal (GI), Neurological, Oncology,
Endocrine, and Respiratory Systems. Diseases associated with increased levels of zonulin
have been suggested to be auto-immune; but, there is reason to consider that symptoms
related to increased zonulin levels may be seen in other diseases not yet classified as
having an autoimmune component (Fasano, 2011; Fasano, 2012). Further research is
needed to elucidate these other diseases. However, symptoms and mechanisms related to
increased zonulin have been described in GI, neurological, endocrine, and respiratory
systems.
Gastrointestinal System
Zonulin was first generally identified as a regulator of intestinal permeability and
has since been implicated in the pathogenesis of celiac disease and colitis (Wang et al.,
2000; Fasano et al., 2000; Duerksen, Wilhelm-Boyles, Veitch, Kryszak, & Parry, 2010;
Cipriani et al., 2011). In cases of Celiac disease, increased permeability in the small
intestine allows gliadin to cross the lamina propria, activate an intramucosal immune
cascade, and result in villous destruction and/or crypt heterotrophy (Duerksen et al.,
2010). The intramucosal immune cascade is a first-line series of immune interactions for
stimulation of immunoglobulin A (IgA) in response to foreign particles. Studies using
real-time polymerase chain reaction (PCR) to quantitate zonulin expression levels found
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increases with celiac disease activity (Tripathi et al., 2009). A study comparing
permeability, antibody testing, and diet from zonulin levels in tissue found that zonulin is
constitutively up-regulated in celiac disease patients, remaining elevated but not
correlating well with histology (Duerksen et al., 2010). Comparisons between lab tests
showed 100% sensitivity and specificity in antibody levels predicting abnormal of small
intestine tissue compared to only 83% for permeability testing using lactose mannitol
(LM) tests (Duerksen et al., 2010).
To date, all of the tests associating intestinal permeability with ASD have been
measured using LM tests (De Magistris et al., 2010; D’Eufemia et al., 1996). The LM test
involves oral administration of a solution of mannitol and lactulose with subsequent
assessment of small intestine absorption measured by a six hour urine collection (Cooper,
1984). For children, LM testing has been used to determine allergies and intestinal
permeability, but the methods of oral administration and collection are very difficult to
obtain due to the use of diapers and inability of children to anticipate the need for
urination and bowel movements. Enzyme linked immunosorbent assay (ELISA) testing
of zonulin may provide novel methods for measuring intestinal permeability (Flanagan et
al., 2014).
Comparison of tests showed significant relationships between permeability and
serum zonulin levels in patients with destructive intestinal histology, but elevated levels
of zonulin with normal intestinal histology limited the use of zonulin for clinical
monitoring (Duerksen et al., 2010). Tissue specific differences in the ubiquitous
expression levels of zonulin, long term exposure rates to increased serum zonulin, and
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gene activation patterns associated with zonulin may explain why zonulin has not been
useful in clinical monitoring. A study of zonulin levels in patients with gastroesphogeal
reflux disease and normal healthy controls found ubiquitous expression of zonulin at 2.23.6ng/µg in the stomach and esophagus (Wex et al., 2009). The ubiquitous expression of
zonulin is thought to be a result of its role in epithelial barrier function from pathogens.
Further research is needed to identify gene interactions with serum zonulin and to
determine if zonulin levels can be used for clinical monitoring.
Several studies have examined gliadin activation of zonulin and how serum
zonulin levels can monitor celiac disease. A study by Fasano et al. (2000) showed that
IgA anti-zonulin levels are increased in acute phase celiac disease at 21% (p<0.0001) but
no increase is seen in IgG levels (Fasano et al., 2000). Baseline levels of zonulin remain
increased for celiac patients compared to those in remission and healthy controls; dietary
intervention always resulted in a return to baseline zonulin levels after 3-6 months of
implementation (Fasano et al., 2000). The return to baseline levels indicate that increased
permeability is reversible and dietary intervention may be a possible intervention upon
presentation of disease.
Zonulin associated with colitis has also been studied in mice models. Bile acid
receptor (GPBAR-1) knockout mice demonstrated increased expression of zonulin-1
mRNA, decreased expression of occludin messenger ribonucleic acid (mRNA) (p <0.05),
and altered sub-cellular distribution along the apical border of colonocytes and vascular
endothelial cells (Cipriani et al., 2011). Additionally, there was an increase in CD8+cells
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and severity of colitis in the GP-BAR1 knockout mice associated with diarrhea and loss
of mucous cells (Cipriani et al., 2011).
Neurological System
The blood brain barrier (BBB) is a complex system of membrane proteins that
form TJ which facilitate control of the flow of molecules in and out of the central nervous
system (Liu, Wang, Zhang, Wei, & Li, 2012). Physiological conditions associated with
changes in the BBB include Alzheimer’s disease, chronic inflammation, diabetes
mellitus, human immunodeficiency virus, and abuse of drugs such as methamphetamine,
cocaine, and morphine (Liu et al., 2012). Affinity column purification identified that
zonulin binds to human brain tissue (Lu et al., 2000). This implies that zonulin may
regulate the BBB allowing substances interrupt barrier function and alter the integrity of
the actin filaments. In an in vitro BBB model using rat brain microvascular endothelial
cells (RBMECs), zonulin increased the transmigration of human neural progenitor cell
lines across the RBMECs and increased epidermal growth factor function (DiazCoranguez et al., 2013). This study was the first to show that pre-HP2 binds to a surface
receptor that opens the BBB and activates a signal pathway that activates phospholipase
C and protein kinase C, polymerizes actin, and contracts the perijunctional action-myosin
ring allowing zonulin to alter the shape and function of nerve cells (Diaz-Coranguez et
al., 2013; Ivanov et al., 2010). The role of zonulin in the BBB targets it in processes that
direct migration of neural stem cells to sites of injury, which indicate its importance in
medicinal interventions (Diaz-Coranguez et al., 2013).
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Endocrine System
The endocrine system synthesizes and secretes chemicals into the body to regulate
growth, metabolism, and sexual development (Coelho, Oliveira, & Fernandes, 2013).
Within this system, increased zonulin levels have been associated with obesity and type 2
diabetes mellitus (Fasano et al., 2000; Jayashree et al., 2014; Moreno-Navarrete, Sabater,
Ortega, Ricart, & Fernandez-Real, 2012; Zak-Gołąb et al., 2013). Obese individuals have
a significantly higher concentration of zonulin than non-obese individuals (12.5±4.6 to
9.3±5.1, p=0.007) (Moreno-Navarrete et al., 2012). Associations between increased
levels of zonulin and obesity were specifically related with increases in body mass index,
waist to hip ratio, fasting insulin, fasting triglycerides, uric acid, IL-6, low levels of highdensity lipoprotein-cholesterol, and decreased insulin sensitivity (Moreno-Navarrete et
al., 2012). Another study by Zak-Gołąb et al. (2013) evaluated 50 obese individuals
compared to 30 normal weight individuals. These researchers found that obese
individuals had a mean zonulin level of 8.2ng/mL (p < 0.001) compared to a mean
zonulin level of 5.4ng/mL in normal weight controls (Zak-Gołąb et al., 2013). The study
also found positive correlations between plasma zonulin levels and age (r = 0.43, p <
0.001), body mass (r = 0.30, p < 0.01), body mass index (r = 0.33, p < 0.01), fat mass (r =
0.31, p < 0.01) and fat percentage (r = 0.23, p < 0.05) (Zak-Gołąb et al., 2013).
A study by Jayashree et al. (2014) confirmed elevated circulating serum zonulin
levels (796 ± 55pg/mL, p <0.001) in individuals with type 2 diabetes mellitus compared
to healthy controls (3.96 ± 0.16pg/mL). These studies suggest that zonulin may play a
role in metabolic disturbances. Further research is needed to determine if it is due to
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increased intestinal permeability, loss of intestinal barrier function, or disruption in
metabolic pathways.
Relationships between zonulin levels and diabetes have been explored using both
animal and human studies. Animal models using rats determined relationships between
zonulin, intestinal permeability, and glucose levels. Watts et al. (2005) found serum
zonulin levels were correlated with intra-luminal zonulin, increasing prior to increases in
glucose and development of type 1 diabetes. In the rat model studies, type 1 diabetes
developed 25 days after zonulin increased intestinal permeability (Watts et al., 2005). In
patients with type 1 diabetes, increased zonulin levels (0.83±0.05ng/mg) were higher than
their “normal” relatives (0.62±0.07ng/mg) and healthy controls (0.21±0.02ng/mg)
(Sapone et al., 2006). No correlations were found between serum zonulin levels and age,
sex, diagnosis of type 1 diabetes, duration of type 1 diabetes, daily insulin dose,
hemoglobin A1c, or serum glucose levels (Sapone et al., 2006). This study provided
evidence that increased intestinal permeability of type 1 diabetes was correlated to
increased serum zonulin levels (Sapone et al., 2006).
Respiratory System
The development of acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) result from pneumonia, aspiration, trauma, sepsis, and associated
disorders such as pancreatitis and drug overdose (Matthay et al., 2003). Lung
permeability is typically measured by albumin leak to indicate severity as failure of
treatment can lead to alveolar edema or hemorrhage (Rittirsch et al., 2013). A recent
study exploring the unidentified molecular mechanisms of ALI found that administration
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of zonulin antagonist AT-1001 reduced albumin leak by 67%; reduced the number of
leukocytes (mostly neutrophils) by 25%; and reduced proinflammatory cytokines IL-6
and tumor necrosis factor  (TNF-) (Rittirsch et al., 2013). Exposure to both forms of
zonulin showed increased lung permeability in mouse models. Rittirsch et al. (2013)
found that 20µg of pre-HP2 indicated a 3.2-fold increase in lung permeability and HP2
showed a 2.6-fold increase in lung permeability. The addition of zonulin to human serum
activated complement demonstrating its role in barrier function (Rittirsch et al., 2013).
Links Between Zonulin and ASD
Zonulin associations with disease are actively being explored to better understand
the molecular pathways and mechanisms of proteins. Hallmarks of cancer and
pathopysiological changes that are only characteristic of cancer show involvement of
zonulin in different cancers. This work has evolved from effecting the onset of diarrhea
during chemotherapy to zonulin involvement in therapy and radiation treatments (Russo
et al., 2013). A study of breast cancer patients showed that GI symptoms (29% with
diarrhea) increased on day 14 of chemotherapy compared to no GI symptoms at baseline
(29.86±1.27 and 24.7±0.94, p=0.02) (Russo et al., 2013). The GI symptoms were
accompanied by a day 14 increase in intestinal permeability (0.067%, p=0.001) (Russo et
al., 2013). Over the 21 day chemotherapy treatment, total serum zonulin levels did not
change; however, circulating levels of glucagon-like peptide 2 (GLP-2) and EGF showed
significant decreases (p=0.0044 and p=0.004 respectively) until reaching a plateau at
which point no further decrease was observed (Russo et al., 2013). The stability of
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zonulin levels during treatment indicates they are independent of chemotherapy (Russo et
al., 2013).
The study of zonulin levels in glioblastomas showed that zonulin expression
controls intercellular communication in two ways: increased v-kit Hardy-Zuckerman 4
feline sarcoma viral oncogene homolog (c-kit) expression and activation responsible for
tumor aggression and effectiveness of tyrosine kinase inhibitor therapies (Skardelly,
Armbruster, Meixensberger, & Hilbig, 2009). Results from human glioma studies
provided evidence that zonulin expression correlated with tumor aggression more
specifically than expression of c-kit, suggesting that zonulin levels may indicate the
degree of disruption in the blood brain barrier and blood vessel walls (Skardelly et al.,
2009). Further research is needed to determine associations between zonulin and genomic
mutations that lead to cancer and suggestive therapy options.
A particular area of interest is the role of zonulin in Autism Spectrum Disorders.
Autism Spectrum Disorder (ASD) describes an array of developmental brain disorders
that are associated with multiple levels of symptoms, cognition, language, and behavior
presentations. The Centers for Disease Control and Prevention (2014) indicates that 1 in
68 children in the United States have ASD. Symptoms of ASD include social
impairment, communication difficulties, and repetitive and stereotyped behaviors
(American Psychiatric Association, 2013). However, additional symptoms have been
reported of food allergies, acid reflux, vomiting, bloating, stomach pain, diarrhea, and
constipation (U.S. Department of Health and Human Services, National Institutes of
Health, 2011). No studies in the literature report serum zonulin measurements of
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individuals diagnosed with ASD, but many connections can be made based on
overlapping mechanisms.
The GI and neurological systems demonstrate two examples that point toward the
involvement of the zonulin pathway. Autism spectrum disorders have long been
associated with GI issues. According to the Autism Research Institute (2013), 70 % of
children with ASD have GI symptoms; however, these are sometimes difficult to
recognize due to communication difficulties between the child, parents and healthcare
providers. The spectrum of phenotypic expression and gene interactions related to ASD
and GI issues make GI or ASD disorders challenging to diagnose. In a large registrybased study of 589 individuals, Wang, Tancredi, & Thomas (2011) reported 42% of
children with ASD had GI problems including constipation and diarrhea compared with
their unaffected siblings (12%). Interestingly, ASD and GI disorders, such as celiac
disease, have increased at approximately the same rates over the past 10 years to a
prevalence of 1 in 88 children (Centers for Disease Control and Prevention, 2012; RubioTapia, Ludvigsson, Brantner, Murray, & Everhart, 2012). Table 2.2 identifies symptoms
related to GI disorders and diagnostic evaluations in patients with ASD (Buie et al.,
2010).
Table 2.2
Diagnostic Evaluation of GI Symptoms and Disorders in Individuals with ASDs
Symptoms
Associated Gastrointestinal Disorder
Sleep disturbance
GERD
Self-injurious behavior, tantrums,
Constipation, GERD, gastritis, intestinal
aggression, oppositional behavior
inflammation
Chronic diarrhea
Malabsorption, maldigestion
Straining to pass stool, hard or infrequent
Constipation
stool

43

Abdominal discomfort

Constipation, GERD, intestinal
inflammation, malabsorption, maldigestion
Flatulence or bloating
Constipation, food allergies, enteric
infection
Any or all of the above
Familial adenomatous polyposis, irritable
bowel syndrome
Table 2.2 Diagnostic Evaluation of GI Symptoms and Disorders in Individuals with
ASDs adapted from Buie et al., 2010.
One of the symptoms, the amount of undigested food, raises concern for passage
through the TJ and the physiological effects it may have on the body. Undigested food in
the form of large immunogenic peptides or intact proteins may reach the lumen of the
small intestine due to evasion of gastric fluid and proteolytic enzyme hydrolysis (Menard,
Cerf-Bensussan, & Heyman, 2010). Undigested food particles may pass through the TJ
stimulating an immune response. Similarly, drug molecules may pass through the tight
junctions of the intestine leading to immune reactions, disease, or toxicity (Ju & Uetrecht,
2002). Drugs are classified based on solubility and permeability according to the
Biopharmaceutics Classification System; permeability determination is made from
pharmacokinetic studies, in vivo intestinal perfusion, in vitro permeability using tissue
biopsies, and Caco2 monolayer studies (Chavda, Patel, & Anand, 2010).
The basis for determining zonulin expression levels in individuals with ASD is
found by precedent of intestinal permeability in individuals diagnosed with ASD and
correlations between severity of autism spectrum disorders and severe gastrointestinal
diseases. D’Eufemia et al. (1996) identified that 43% of autistic patients displayed altered
intestinal permeability using lactulose/mannitol (LM) tests. D’Eufemia et al. (1996)
speculated that intestinal permeability increased the passage of food peptides through the
gut leading to subsequent behavioral abnormalities.
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De Magistris et al. (2010) performed tests on 90 children with Autism Spectrum
Disorder and 146 of their first-degree relatives. Results revealed 36.7% of ASD patients
and 21.2% of their first-degree relatives have abnormal intestinal permeability (De
Magistris et al., 2010). Once again, intestinal permeability was determined by LM tests.
For ASD patients and their first-degree relatives there was a 2-to 3-fold increase in
lactulose compared with mannitol recovery (De Magistris et al., 2010). Interestingly,
most of the ASD patients and relatives were negative for antibodies or antigens to food
allergies (De Magistris et al., 2010). The toxic reactions without the presence of
antibodies or antigens may indicate that zonulin association with gastrointestinal disease
is a result of constitutive action of the toxic effects of the protein at increased levels.
Furthermore, the correlation between zonulin levels and severity of autism is
supported by the results from Adams, Johansen, Powell, Quig, & Rubin (2011). These
researchers found that children with more severe forms of autism are likely to have more
severe gastrointestinal symptoms. Gastrointestinal symptoms were measured based on a
GI severity index using a combined score of constipation, diarrhea, stool consistency,
stool smell, flatulence, and abdominal pain. Children with higher Autism Treatment
Evaluation Checklist scores had gastrointestinal severity index scores greater than 3
(p=0.00002) (Adams et al., 2011).
Neurological mechanisms are of major importance in linking ASD and zonulin,
and supporting correlation between increased zonulin levels and severity of neurological
symptoms. The study by Skardelly et al. (2009) implicated zonulin expression levels in
disruption in the BBB and blood vessel walls suggested that zonulin may be correlated
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with neurological levels of severity in individuals with ASD. Studies of zonulin may help
determine if disruption of the BBB leads to disruption of brain development and
signaling occurs in utero from maternal immune activation or during infancy. A
connection can already be made through signal transducer and activator of transcription
3 (STAT3) activation by IL-6. Using animal models, Parker-Athill et al. (2009) found that
IL-6 mRNA levels remain elevated up to 24 weeks after birth suggesting in utero
inflammatory pathogenic effects. Such a connection could lead to development of
diagnostic testing for ASD and early diagnosis.
Conclusion
Identification of zonulin as a modulator of intestinal permeability has expanded
the understanding of tight junctions. Research has implicated increases in zonulin to
physiological effects in the Gastrointestinal, Neurological, Respiratory, Endocrine
systems, and oncological diseases. The ability of zonulin to allow macromolecules and
antigens to pass through the TJs in the intestine and the BBB challenge classical theories
of inflammatory pathogenesis based solely on genetics and environmental triggers
(Fasano, 2011). The regulation and reversal of intestinal permeability by zonulin
proposes a new theory that pathogenesis, in general, is not self-perpetuating but can be
interrupted (Fasano, 2011). Based a review of the literature published thus far, a model is
proposed that uses increased serum zonulin levels and comparisons of the physiological
effects of zonulin and phenotypic assessment data to implicate severity of disease states.
Figure 2.2 shows the proposed zonulin pathway to disease.
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Figure 2.2
New Zonulin Model of Pathogenesis

Figure 2.2 illustrates the zonulin pathway that produces symptoms and diagnosis of
disease.
Additional research is needed to understand the zonulin pathway and its
associated diseases. It will be important to identify ranges of zonulin, highlight specific
symptoms or a phenotypic threshold for disease, identify gene interactions and
environmental triggers, and indicate zonulin regulation of drug metabolism. The need for
understanding zonulin’s role in protein molecular pathways and genomic interactions is
important.
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Abstract
Autism spectrum disorder (ASD) is a developmental disorder that is accompanied
by an array of symptoms affecting behavior, communication, cognition, and multiple
organ systems. Early diagnosis of ASD is being sought to reduce the severity of
symptoms, increase daily function, and maintain quality of life. Social media such as
Twitter, Facebook, LinkedIn, chat rooms, and blogs present resources to the public that
allow them to capture experiences and symptoms of autism or other diseases in real time.
This study explores and captures self-reported material posted in social media using
Radian6 to identify patterns and themes related to autism and GI symptoms for the
purpose of translating that knowledge into healthcare applications at the individual and
corporate levels.
Keywords: social media, ASD, autism, autism spectrum disorders, Radian6
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Exploring Autism and GI Symptoms using Radian6
Autism spectrum disorder (ASD) is a developmental disorder that is accompanied
by a myriad of symptoms affecting behavior, communication, cognition, and multiple
organ systems (American Psychiatric Association, 2013). Many genes have been
implicated with risk associated with disorder development, but the etiology of autism
remains unknown (Gilling et al., 2013; Handrigan et al., 2013; Liu et al., 2013; Sarachana
& Hu, 2013). Focus has recently moved toward early detection of ASD, which is
pertinent to minimize symptoms and maintain quality of life. With no diagnostic test
available, early detection relies autism rating scales and evaluation checklists that rely on
behaviors and observations made by parents, caregivers, or healthcare professionals
(Geier, Kern, & Geier, 2013; Nah, Young, & Brewer, 2014).
The development of social media provides an open platform to witness a variety
of self-reported experiences related to autism. A recent study by Mazurek (2013)
identifies 79.6% of 108 ASD individuals used social media sites to connect with others.
In another study, Mazurek and Wenstrup (2013) found children with ASD spent little
time using social media and more time playing video games than their siblings who
followed typical growth and development guidelines. Additionally, a qualitative study
was performed using chat logs of twelve young people diagnosed with attentiondeficit/hyperactivity disorder and ASD (Ahlstrom & Wentz, 2014). The chat logs
identified two themes of ‘fighting against an everyday life lived in vulnerability” and
“struggling to find a life of one’s own” (Ahlstrom & Wentz, 2014). These studies using
internet and social media suggest that these devices or applications may provide methods
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for diagnosing, monitoring, or treating ASD (Ahlstrom and Wentz, 2014; Mazurek, 2013;
Mazurek & Wenstrup, 2013). Topics focusing on communication, management, and
health related concerns dominate social media and findings indicate that after initial
participation, engagement of social media decreases over time with autistic individuals
(Hong, Yarosh, Kim, Abowd, & Arriaga, 2013).
Studies surrounding autism and gastrointestinal (GI) symptoms have focused
primarily on self-report from questionnaires and surveys (Kang, Wagner, & Ming, 2014).
Internet based approaches to ASD intervention consistently indicate increases in quality
of life (Garcia-Villamisar and Dattilo, 2010; Wentz et al., 2012). Evidence suggests that
facilitating interaction with media, exercise, games, crafts, and events decreases stress
levels and increases quality of life for individuals with ASD (Garcia-Villamisar and
Dattilo, 2010; Wentz et al., 2012). A review of the related literature was unable to
identify publications directly mention using social media as a translational tool to study
ASD for the purpose of targeting pathways of disease mechanisms or for developing new
interventions and approaches. The purpose of this study was to explore and capture selfreported material posted in social media in order to identify patterns and themes related to
autism and GI symptoms for the purpose of knowledge translation to healthcare
application.
Methodology
A non-experimental exploratory study was conducted using Radian6 to mine
social media data. Radian6 software allows for data mining across multiple social media
outlets such as Facebook, Twitter, blogs, and Media. Data was captured at the end of
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each month from September 1, 2013 to November 30, 2013. Parameters in Radian6 were
set to collect only data in the English language in the United States (U.S.). All media
types were included. The study data was present in the public domain, free of
subscription or login requirements. Following the rules of repeated entry elimination by
elastic matching identification, data was excluded if it was a repeated entry having ≥90%
identity with a previous post (Zhao et al., 2013). In addition, information was excluded if:
(1) the source required membership dues, site registration, or login; (2) the hit was an
advertisement, sub-headline only, or random text with no contextual information; or (3)
the entry contained ≥ 90% sexually related or derogatory comments or content.
Filtering Criteria
Search terms entered in Radian6 were based on a literature review of
gastrointestinal symptoms commonly seen in ASD individuals. Search terms of GI
symptoms were combined with “AND CONTATINS AUTISM” and were separated with
“OR.” For example, the search terms read (“food allergies” AND CONTAINS “autism”)
OR (“nausea” AND CONTAINS “autism”). The search strand continued until all GI
symptoms had been added. See Table 3.1 for a list of GI symptoms seen in patients with
autism, which were used as keywords.
Table 3.1
GI Symptom Keywords for Radian6 Search Criteria
1.
2.
3.
4.
5.
6.

Food Allergies
Nausea
Reflux
Digestion
Infection (Bacteria, parasite, OR yeast)
Bloating OR Flatulence
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7. Abdominal pain
8. Bowel obstruction
9. Constipation
10. Diarrhea
11. Stool
12. Cancer
The keywords were based on common symptoms related to the GI system and ASD. It
was difficult to define a boundary of vocabulary used by the public for autism or GI
problems due to the spectrum of symptoms. The keywords provide a boundary within
social media to reduce the data collection from over a million hits using only autism as a
search term, to a collection of 6878 data entries.
Data Analysis
Using the specified filtering criteria, Radian6 yielded 6878 entries. The first stage
of data analysis indicated that the majority of social media information was being
dispersed through Facebook (49%) and Blogs (21%).
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Figure 3.1
Dispersion of Information in Social Media
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Figure 3.1 Dispersion of Information in Social Media. [The pie graph above shows the
percentage of hits per media outlet across a total of 6878 entries from Radian6 for months
September, October, and November. The coded data was not used for the dispersion
diagram in order to represent which type of social media would most likely be seen by
the public when searching for information. The information shows that Facebook tends to
be the most common form of social media discussing autism and GI symptoms. Radian6
also produced comment counts for each month of data collection. Across all three months
of data, interventions were most frequently commented on, with topic of gluten being in
the top 2 for all three months. Baby development was also included within the top 5
topics of comment across all three months.]
In order to prepare the data for analysis, it was exported from Radian6 into Excel
in the form of a .csv file at which point each entry underwent manual examination. Each
entry was accessed in full via its corresponding web address. A research team member
read the entry and coded it based on contents. Entries were tagged for deletion if they did
not meet the inclusion criteria as discussed above. The “FIND” function in Excel assisted
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in the identification of repeated entries, which could be identified by web address,
contents, or author. Entries failing to meet the criteria were discarded before upload into
QSR International’s NVivo 10 software for further analysis. Of 6878 entries identified in
social media, only 1930 hits contained contextual information related to autism and GI
symptoms. The remaining 1930 social media hits after initial cleaning in Excel were
dispersed among several media providers. The top four media providers included
Facebook (49.9%), wordpress (13.7%), generic blogs (11.2%), and forums (10.5%).
Twitter posts contained the most repeated content which was tagged for removal from the
data set.
Manual examination of the 1930 hits in Excel yielded 20 coded categories. These
categories included links to “autism”, “pathology”, “no links to autism”, “symptoms”,
“interventions”, “consequences”, “feelings”, “siblings”, “age at diagnosis”, “age at
onset”, “coping mechanisms”, “testing”, “intestinal permeability”, “co-morbid diseases”,
“retraction of autism diagnosis”, “lacks deficits needs”, “questioning”, “family history”,
“ASD improvements”, and “indications of pharmacogenomic testing”. Each entry was
coded for one or more category based on the contextual information. The “no links to
autism” category was included to capture all stake holder points of view, and to address
the final quantity of these hits was enough to statistically support the null hypothesis.
After coding three months of information, it was determined that some categories could
be collapsed to better represent the data. The “co-morbid diseases” category was
combined with the “symptoms” category, the “retraction of autism diagnosis” category
was combined with “ASD improvements,” and cases within the “indications of
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pharmacogenetic testing” category were re-coded to either interventions or symptoms.
The final category of symptoms was intended to look at all symptoms associated with
ASD and to answer the research question, “what symptoms are expressed in recorded
social media data related to ASDs?” Additionally, the categories were used to identify
themes related to ASD from social media. Categories of “lack deficit needs”, “ASD
improvements”, and “interventions” were intentionally directed at answering the research
question, “what are the facilitators and barriers of social media use in relation to ASD?”
The re-categorized data was uploaded into QSR NVivo for further content analysis.
In NVivo, tree nodes were created to catalogue categories into hierarchical
structures, and other categories were collapsed into more generalized categories. In total,
18 categories emerged from the 1930 social media hits. The 18 categories had a
combined 24,127 coded references. The term “coded references” refers to words or
phrases from each hit that are coded to a particular node or multiple nodes. The term
“node” is used synonymously with category. The final categories included “siblings”,
“feelings”, “proposed links”, “family history”, “pathology”, “coping mechanisms”,
“consequences”, “media provider”, “no link to autism”, “lack deficit needs”, “age at
onset”, “intervention”, “questions”, “improvements”, “symptoms”, “age at diagnosis”,
“abilities”, and “quotes”. The following includes the major findings for each category.
Results
Siblings
The category of “siblings” contained 64 out of 1930 hits across the three months
with 1943 coded references. Siblings were defined as a brother or sister relationship,
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adopted or blood relative related to an individual with autism. The references coded into
the “sibling” category referred to a number of children in the family identifying affected
or not, gender, or symptoms. The most frequently mentioned terms were words that
indicated autism (autism, ASD, or affected) was present among children (children, kids,
sibling, or siblings) for weighted percentages of 15.86% (55 counts) and 10.37% (36
counts) respectively. Most families had one or two children with both terms represented
at 3.17% (11 counts) each and of these, boys were most commonly represented (2.59% or
9 counts). These findings lend support to the prevalence that boys are five times more
likely to be affected by autism than girls (Centers for Disease Control and Prevention,
2014). The word cloud generated by QSR NVivo for “siblings”, as shown in Figure 3.2,
illustrated words most commonly coded under the sibling node.
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The size of each word in the word cloud is proportional to the number of times
that word appears in the node. The word count also increases the weighted percentage a
word has within a node. The word cloud provides a visual interpretation of the numerical
values without having to insert lengthy tables, and for the purposes of qualitative research
the word cloud offers a more contextual interpretation of the data.
Figure 3.2
Siblings Word Cloud

Figure 3.2 Siblings Word Cloud. [The word cloud illustrates autism, affected, children,
siblings, two, one, and kids were the most frequently counted words.]
Feelings
Feelings represented the emotions, thoughts, and physical response related to
autism reported through social media hits. This category contained 178 out of 1930 hits
with 1936 coded references. The majority of hits was self- reports from caregivers or
parents of individuals with autism; indicated by word counts that included child
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(weighted percentage of 1.28% or 40 counts) or children (weighted percentage of 0.45%
or 14 counts). Figure 3.3 is a word cloud produced from all the hits within the “feelings”
category.
Figure 3.3
Feelings Word Cloud

Figure 3.3 Feelings Word Cloud. [The word cloud shows the words autism, child, know,
like, people, parents, and time are most frequently counted.]
Many of the caregivers or parents expressed concern, frustrations, or reactions to
the diagnosis and management of autism. One of the most important terms in the
“feelings” category was to know which terms took on multiple meanings. The term
“know” was mentioned 28 times for a weighted percentage of 0.90%, but it yielded many
different meanings as shown in the paraphrased excerpts below:
Caregivers or parents know what is best for his/her child
Tell us [caregivers and parents] something we do not know already
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I [individual with autism] can choose the best for myself because I want to be
well.
Call me an autistic person, but do not define me by my disease as a person with
autism. I have a name so introduce me by my name so that people can know who
I am.
Nothing could be worse than watching my child in pain. My child bites, pinches,
and hits his/her body to the point of bleeding, bruising, and swelling.
The term “know” took on many different forms. First, the act of “knowing” from
the perspective of a parent or caregiver, described understanding their child’s response to
treatments or interventions. In many cases, the parent or caregiver identified the
symptoms of autism first and then sought out an explanation. This suggests a need for an
instrument to record home experiences and log response to interventions. Some parents
make daily logs that record their child’s response to foods, medications, and therapies.
These become valuable to help the clinicians manage the treatment of autism. This
resource also points toward the importance of a strong relationship and communication
between the caregiver, parent and the clinicians. In almost all cases the parent or
caregiver fulfills the role of patient advocate.
Secondly, the term “know” referred to understanding or wanting to know more
about autism as a disease. Even though there is a plethora of information available on the
internet regarding autism, parents or caregivers often question the reliability of the
information. As pointed out in the “lack deficit needs” category, information from the
internet can be contradictory in nature and not always scientifically based. It may be
difficult for parents or caregivers to: (1) locate reliable and scientifically based
information; (2) understand ASD because of the extensive use of scientific or clinical
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jargon; and (3) comprehend the full meaning of the information due to the emotional and
physical stress they are experiencing. Additionally, social media suggests that most
parents want to know and understand their child(ren); which can be difficult due to
problems with communication and isolation. Parents want to know what their child likes
and does not like, and they want to know and understand their pain. From the data
entries, several examples of communication devices or methods emerged as helpful tools
in relaying messages between the individual with autism and other individuals. For
example, sign language or picture boards were found to be useful in stimulating
communication at home.
Another perspective mentioned in social media was that of the affected individual.
The desire of the affected individuals to feel normal was present in social media entries.
On a personal level, individuals with autism want to be treated equally with non-affected
individuals on a personal level. They appreciated others treating them as normal not as
different and including them in daily activities with other children their age or
introducing them to new people without identifying their disease. This reinforces the
stigma of having a mental disorder (Link & Phelan, 2013; Pescosolido, Medina, Martin,
& Long, 2013; Szeto, Luong, & Dobson, 2013; Thoits, 2013). Individuals with autism
desire respect as an individual and they want to be included in a discussion about the
future interventions. According to this data, individuals with ASD want and should have
a voice in the outcome of their future.
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People with autism see the same world in a different way
Some of the strongest feelings represented in the contextual data are displayed in table
3.2.
Table 3.2
Types of Feelings and Weighted Percentages
Type of Feeling
Weighted Percentage (%)
need or needs
0.44
fear
0.42
believe
0.29
hard
0.29
want
0.29
bad
0.26
denial
0.26
good
0.26
guilt
0.26
pain
0.26
think
0.26
try
0.26
care
0.22
cause
0.22
help
0.22
love
0.22
talk
0.22
change
0.19
difficult
0.19
find
0.19
give
0.19
health
0.19
joy
0.19
stress
0.19
wrong
0.19
Table 3.2 Types of Feelings and Weighted Percentages.
Many of the feelings either surround the initial reaction of diagnosis or the feeling is a
reaction to demands and comments of society. The following is an example of a
combined reaction that clearly expresses the feelings of the parent.
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The doctor gave the diagnosis and I [the caregiver] became overwhelmed with
fear, guilt, and extreme sadness. I was nauseated from the news… feeling like I
had let my child down. I felt like it was fault and that my child’s future would be
hindered by this diagnosis. It was the worst feeling in the world. Comforting and
reassuring words were not accepted. My gut feelings told me to seek a second
opinion and reject this diagnosis. I refused to accept that autism is a permanent
disorder and that nothing can be done. I tried to think of ways to keep my child
from getting sick, ways to improve the current state, and ways to help others who
are in the same situation. I immediately began to research autism. I read
everything I could find related to healing Autism.
My spouse was working multiple jobs to provide for our family. I stayed home
with my children and worked from home. One of the hardest, darkest times in my
life was learning of our child’s diagnosis of autism. No one seemed to
understand… We heard all kinds of comments from people. Most of the things we
heard were negative about our parenting or about our children. The comments
made it seem like we had done something wrong- that this was our fault. I
searched in desperation for an answer. We mourned the ideas and aspirations that
our child would never achieve.
Proposed Links
Proposed links was defined as elements suspected to have a relationship with
autism, but remain under scientific investigation. The items listed under this category
produced much debate among respondents. Proposed links contained 1344 out of 1930
hits with 1934 coded references. Below is the word cloud produced for the “proposed
links” category.
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Figure 3.4
Proposed Links Word Cloud

Figure 3.4 Proposed Links Word Cloud. [The word cloud shows that symptoms, food,
vaccines, gut, brain, and children were the most frequently counted words associated with
proposed links with autism.]
Interestingly, the raw data counts listed autism (536 counts or 7.79%), gut (82
counts or 1.19%), vaccines (77 counts or 1.12%), and children (72 counts or 1.05%) as
the top four words counted under the category of proposed links. Further evaluation of
the word counts, revealed that 174 of 1344 counts contained terms synonymous with
gastrointestinal function or location followed by terms for vaccines (143 counts) and
children (98 counts). The coded hits suggest there is a relationship between the GI system
and ASD. In this study, the majority of coded entries under gastrointestinal terms refer to
symptoms related to autism or the GI system present during early years before diagnosis
of autism. It is unclear from the data whether autism or GI symptoms occur first, or if a
causal relationship exists.
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Unlike the references coded for gastrointestinal, the majority of hits under
vaccines stemmed from debate surrounding the well known and re-tracted article
published in the Lancet by Wakefield et al (1998) and warning labels produced by
vaccine manufacturers. For the purpose of this study, vaccines are acknowledged as a
potential mechanism by which an individual can be exposed to bacteria or viruses which
trigger a cascade of events that lead to diverse symptoms. However, these pathways
require more scientific research to implicate them with the onset of autism (Tomljenovic,
Blaylock, & Shaw, 2014).
Family History of Individuals with ASD
Family history accounted for 62 of 1930 hits with 1932 coded references. Family
history was defined as self described symptoms, exposures, diseases, or events that
occurred in the life of a person who indicates a relationship with an autistic proband.
Mothers were the most frequently reported (18 counts or 1.82%) in relationship with the
proband and among mothers pregnancy (15 counts or 1.51%) was most frequently
discussed as having a possible connection to the affected individual. Autoimmune disease
(7 counts or 0.71%, diabetes 3 counts or 0.30%), depression (6 counts or 0.61%), pain (6
counts or 0.61%), gastrointestinal (bowel 5 counts or 0.50%, digestive 3 counts or 0.30%,
celiac 3 counts or 0.30%, constipation 3 counts or 0.30%), allergies (4 counts or 0.40%),
arthritis (4 counts or 0.40%), fibromyalgia (4 counts or 0.40%), and cancer (4 counts or
0.40%) were most frequently reported diseases and symptoms reported in family history.
Most of the discussion on family history was by families attempting to find an
explanation as to why their child developed ASD.
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Our family does not fit any genetic models of inheritance, since no one on either
side of our families is autistic.
The use of pitocin (6 counts or 0.61%) was the most frequently discussed medication
listed in family history believed to result in a child with autism. One of the particular
problems related to the use of pitocin was the cited “unregulated cap on the highest level
of pitocin allowed.” A recent study by Gregory et al (2013) has found that the risk of
having a child with autism increased with induction and augmented childbirth. Therefore,
a complete pregnancy and birth history are critical.
Figure 3.5
Family History Word Cloud

Figure 3.5 Family History Word Cloud. [Mother and family have the highest word counts
associated with autism and family history.]
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Pathology
Pathology identified 43 of 1930 hits (1931 coded references) with the most
common pathology of autism being related to the gut (gut 12 counts or 1.78%, intestinal
5 counts or 0.74%, digestion 4 counts or 0.59%, gastrointestinal 2 counts or 0.30%) or
bacteria (8 counts or 1.19%) compared to genetic inheritance (DNA 4 counts or 0.59%,
gene 2 counts or 0.30%, genes 3 counts or 0.45%, genetic 3 counts or 0.45%). The results
suggest that social media participants believe genetics play a large role in the pathology
of autism. The relationship between gastrointestinal genes and their relationship to autism
appears to be strong based on pathology key words. Some examples of GI pathways
mentioned in social media include the following:
Failure of digestion that initiates a cascade leading to cognitive decline
Mucosal surface damage of the gastrointestinal tract leading to immune
suppression
Genetic predispositions and environmental exposures leading to unhealthy gut
flora, inflammation, and leaky gut
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Figure 3.6
Pathology Word Cloud

Figure 3.6 Pathology Word Cloud. [Bacteria and gut are the most counted words
associated with autism pathology.]
Coping Mechanisms
Coping mechanisms include 53 of 1930 hits with 1931 coded references. Coping
mechanisms are defined as means by which families or individuals deal with problems
and situations related to autism. The main way families and individuals cope with autism
is through support systems. People (7 counts or 1.01%), kids or children (9 counts or
1.30%), and parents (5 counts or 0.72%) are the top three terms representing support
systems. A support system provides sharing (4 counts or 0.58%) and time (4 counts or
0.58%) to help the families and individuals deal with their stresses related to autism.
People also find resolve in things (5 counts or 0.72%), which most frequently includes
some form of writing activity (writing 3 counts or 0.43%, Facebook 3 counts or 0.43%,
blogging 2 counts or 0.29%). Paraphrased notes from social media hits indicate the
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writing activity allows the people to share their lives, dispel myths about autism, and
share what they have learned.
Figure 3.7
Coping Mechanisms Word Cloud

Figure 3.7 Coping Mechanisms Word Cloud. [The highest ward counts for coping
mechanisms are people, parents, kids, and things.]
Consequences
Consequences were defined as the result of or an effect of any action related to
autism. There were 74 consequences out of 1930 hits with 1931 coded references. Most
consequences effected children (children 9 counts or 1.27%, child 8 counts or 1.13%) or
families as a whole (8 counts or 1.13%). Consequences resulted from the topic of
vaccinations (13 counts or 1.82%), which was two sided. Those who received
vaccinations most frequently reported side effects which lead to controversial belief that
vaccines lead to autism. Secondly, the lack of vaccinations (4 counts or 0.56%) has

81

resulted in increased exposure, presence of diseases that could be prevented (e.g. measles
0.84% or 6 counts) and life-threatening dangerous complications.
Figure 3.8
Consequences Word Cloud

Figure 3.8 Consequences Word Cloud. [The highest word counts for consequences were
children, family, child, people, measles, and vaccines.]
No Link to Autism
There were 55 of 1930 hits that stated that there were no causative links with
autism. Topping this list was vaccines (35 counts or 7.69%) which were clearly indicative
of the retraction and lack of scientific evidence that vaccines cause autism. Celiac (8
counts or 1.76%) was also included in this list due to recent publication that found no
evidence of celiac in autism subjects.

82

Figure 3.9
No Link to Autism Word Cloud

Figure 3.9 No Link to Autism Word Cloud. [Vaccines had the highest word count from
the no link to autism category.]
Lack Deficit Needs
The category of “lack deficit needs” is defined as resources related to autism that
are absent, scarce, or insufficient to meet the needs. This category was made up of 188 of
1930 hits with 1329 coded references. The category was further broken down into the
following subcategories.
Table 3.3
Lack Deficit Needs Sub-Category References
Sub-Category
Problems with medical interpretation
Need for testing or treatment
Cost
Problems diagnosing
Treatment failure
Misconceptions
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Number of Coded References
63
43
36
29
25
20

Access to healthcare
18
Parental interference
14
Need for information
14
Legal representation
11
Access to specialized education
11
Employment
5
Abuse
4
Lack of support
4
Failure of prescription compliance
3
Need for proper labeling
2
Unapproved uses of treatment
2
Failure of assistance program
1
Missing person
1
Table 3.3 Lack Deficit Needs Sub-Category References. [The numbers represent the
coded references within the node.]
The majority of complaints about gaps were focused on meeting the needs of
children with autism, which included deficiencies in doctors (35 counts or 1.16%) and
medical care (16 counts or 0.53%). Problems with pediatricians were noted specifically in
the word count eight times. Of the deficiencies, misdiagnoses and costs or money topped
the list, 0.23% (7 counts) and 0.23% (7 counts) respectively. Examples related to
healthcare include problems with medical interpretation (coded 63 times), lack of testing
or treatment (coded 43 times) and excessive cost of care (coded 36 times). The following
are paraphrased entries from social media that capture these complaints:
The medical approach to medicating individuals with autism relies on trial and
error due to the lack of pharmacogenetic testing. Dosages are adjusted differently
for each person, and one medication may be ineffective or have negative effects
while others are helpful.
Medical expenditures for individuals with ASD are very costly, reaching an
average five times greater than those without ASD.
Pediatricians are reluctant to diagnose ASD early.
Physicians are not trained to find and treat the underlying causes of ASD.
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Health professionals lack training to deal with ASD.
Figure 3.10
Lack Deficit Needs Word Cloud

Figure 3.10 Lack Deficit Needs Word Cloud. [The largest word counts for lack deficits
and needs were children, child, symptoms, doctors, and medical.]
Many complaints mentioned the use of a trial and error approach to treatment, and
some hits even expressed a need for better education and training for healthcare
professionals. Items in the “problems diagnosing” sub-category referred to the inability to
distinguish autism symptoms from other diseases like attention deficit disorder, thyroid
disorders, Lyme disease, Rett syndrome, and 22q13.3 deletion syndrome. Treatment
failure focused on side effects, resistance, or tolerance of drugs.
Examining the sub-category of “employment” indicated ineffective interventions
for autism made it difficult for these individuals to obtain and keep employment. The
sub-category of “employment” showed 100% negative outcomes for employment of
autistic individuals so it was moved from abilities to the lack deficit need category. All of
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the coded references expressed problems in holding a job citing “numerous terminations”
from “being too sensitive to having difficulty concentrating.”
Sub-categories of abuse, lack of support, parental interference, and failure of
compliance or from assistance programs help explain from where problems emerge.
Failure of compliance refers to care givers, parents, or autistic individual’s adherence to
prescribed treatment programs either with medication, diet, or therapies. Parents express
difficulty in forcing children with food aversions or sensitivities to take medicines or
maintain diets. Several ways were offered throughout the data to resolve this problem:
mixing medicine in foods, making the medicines available in different forms (i.e. tablets,
liquids, sub lingual forms, or by injections), or pharmacogenetic testing to prevent trial
and error.
Parental interference occurred when parents or caregivers did not see response in
their child or they saw adverse events in response to intervention methods. In some cases
the caretaker failed to see the symptoms or regression, which led to delayed exposure or
changes in intervention. In other instances, the caretaker failed to see an improvement
and would seek out new interventions or add supplemental or unapproved interventions
to care for their child. Feelings of denial and desire to give the child the best can fuel
parental actions and create counter effects from what is intended. The following are
summarized excerpts that describe the extent of parents over reacting and interfering in
their child’s treatment.
The doctor blames my child’s symptoms on autism without ruling out other
causes.
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The parent or caregiver refuses to take his/her child back to the pediatrician
because of a statement made stereotyping parents of ASD children wanting a
diagnosis for financial assistance.
Some parents try to please their child with ASD so much that the child can get
away with anything. In extreme cases the child completely rules the house with no
parental control.
The parents refused to have their child evaluated for ASD at a young age because
they felt the child’s symptoms were minimal.
An individual with ASD wants to feel independent and gain respect from his/her
parents.
Age at Onset
The age of onset was defined as the self-reported age at which the parent or
caregiver noticed symptoms that were non-typical leading up to a diagnosis of autism.
The age of onset category was made up of 61 out of 1930 hits with 1283 references. The
category was subcategorized to capture the age of onset at birth (18%), 12 months or less
(39.3%), 24 months or less (31.1%), and 36 months or less (6.6%).
Age at Diagnosis
The age of diagnosis was self-reported in 44 of 1930 hits with 540 coded
references. The age of diagnosis was sub-categorized into age in years at diagnosis.
Table 3.4
Age at Diagnosis Sub-categorization into Years
Age in Years
1 year or less
2 years
3 years
4 years
6 years
7 years

Number of References Coded for Age
10
12
11
5
1
2
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8 years
0
9 years
1
10+ years
3
Table 3.4 Age at Diagnosis Sub-categorization into Years.
The youngest individual diagnosed with autism was five months of age and the oldest
was 17 years of age. Most frequently children were diagnosed around one year of age.
Figures 3.11 and 3.12 illustrate age of onset and age of diagnosis. A gap is visible
between age of onset around 12 months and age of diagnosis at two years.
Figure 3.11

Age of Onset for Autism
Spectrum Disorders
40

Percentage from 61 Hits

35
30
25
20
15
10
5
0
Birth

12 Months 24 Months 36 Months
Age

Figure 3.11 Age of Onset for Autism Spectrum Disorders.
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Figure 3.12

Autism Age of Diagnosis
Number of Coded References
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Figure 3.12 Autism Age of Diagnosis
Interventions
The category labeled interventions contained 878 of 1930 hits with 1260
references. Interventions were defined as something that occurs between two points in
time as related to autism. The word count summary identifies diet (164 counts or 1.65%),
therapy (123 counts or 1.23%), and gluten (59 counts or 0.59%) to be the top three ways
to intervene once autism is suspected in a child. The word cloud is shown below.
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Figure 3.13
Interventions Word Cloud

Figure 3.13 Interventions Word Cloud. [The words with the highest count included diet,
therapy, child, children, gluten, food, and supplements.]
Interventions were sub-categorized as “actions”, “supplements”, “diet”,
“therapies”, “medications”, “support”, “specialists”, “medical testing”, “education”,
“tools”, “devices”, “warnings”, or “treatment resistance”. The most common “action”
was early intervention, which seemed to lead to better outcomes through the disease
process. The following are some paraphrased examples from the social media hits:
Early detection of ASD can protect caregivers, parents, and affected individuals
from severe consequences
Young children respond faster to interventions than older children, which improve
their quality of life long term.
Of course, early intervention could not be achieved without helps from other resources or

90

combined actions.
From the sub-category of actions, “helps” were counted 24 times (0.60%
weighted percentage) as the most important term used to define action. Examples of help
include:
helping an individual with ASD with reading and language
helping an individual with ASD re-learn important cues
helping the public understand autism
helping promote studies on gene-environment interaction
Other terms synonymous with help were also indicated as actions of importance such as
advocate or give. Much of the action listed in the entries was two-folded focusing on
learning, gaining knowledge, or relaying positive messages either for the caregiver,
family, or affected individual. In either situation the one acting to provide an intervention
would also gain from his/her actions through personal growth.
For the individual with autism, one of the themes seen under this category
referred to learning or obtainment of skills. Life skills are important to the person in
overcoming developmental delays, obtaining employment, learning, and being able to
function with everyday tasks. One post in social media discussed the impact of life skills
on the individual sharing that experience and coping skills empower students to solve
problems and recognize stress levels. As with any form of intervention, support is needed
to obtain and maintain the resources to make a difference in the disease processes.
Support is another sub-category of interventions containing 119 coded references.
Support is dependent on the actions of many individuals. The word count shows that
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support is influenced most by support groups (3.12%), family (1.40%), books (1.25%),
parents (2.18%), community (0.78%), Facebook (0.47%), and friends (0.47%). Although
specialists were sub-coded separately, they need to be included to provide medical
support and guidance toward treatment options. The most sought after types of specialists
were: chiropractors (3.72%), developmental pediatricians (3.10%), and neurologists
(1.86%). This number was heavily influenced by the increased number of social media
entries by chiropractors versus other medical specialists.
It was apparent, within social media, that parents and caregivers have sought out
unconventional treatments for their children due to deficits in healthcare and failure of
treatments. Many of these unconventional treatments utilize complementary or alternative
treatments (Akins et al., 2014). Supplements (288 references) or diets (281 references).
Oil (3.0%), magnesium (1.64%), vitamins (4.09%), enzymes (1.45%), glutathione
(1.45%), and amino acids (1.09%) were the most frequently mentioned forms of
supplements. Several dietary changes were reported as effective in reducing symptoms
related to autism. These diets included elimination of gluten, casein, dairy, and/or sugar.
Elimination of these four items either individually or in some combination made up 125
hits. Many people had self-reported success with the Gut and Psychology Syndrome
(GAPS) nutritional program (2.52%), commonly referred to as the GAPS diet, which is a
combination of diet, supplementation, and detoxification. Other diets of mention were
organic (1.03%), fermented foods (0.84%), and ketogenic diets (0.84%). Usually, the
incorporation of diet and therapy was seen as beneficial in treating symptoms of autism.
Therapeutic measures and medications differed based on the severity and

92

symptoms manifested in the individual. Speech (3.93%), behavioral (2.62%),
occupational (2.62%), chelation (1.31%), sensory (1.16%), biomedical (1.02%), music
(1.02%), physical (1.02%), play (1.02%), and stem cell therapies (1.02%) were just a few
of the therapies mentioned in social media. Much emphasis was placed on the success of
applied behavioral analysis (2.62%), which is a comprehensive form of therapy that
focuses on modifying behaviors. Although therapy alone can positively impact
behavioral patterns, sometimes the presence of co-morbid diseases or severity of autism
symptoms requires the use of medications as coded in 135 references. Medications most
frequently used by autistic individuals include antibiotics (4.15%), marijuana (3.9%),
Miralax (1.95%), Diflucan (1.22%), Risperdal (1.22%), Ritalin (1.22%), Nystatin
(0.98%), and antidepressants (0.98%). Of course medications used are linked with
symptoms.
While devices made up only 30 of the 1260 references for interventions, posts
demonstrated a need for more integration based on the positive outcomes that have
resulted from their use. Communication (6.14%) was the number one use for devices,
such as iPads (7.89%), computers (2.63%), and special lenses (2.63%). Software
applications were discussed due to their personalization to the user’s needs. Integrated
devices in healthcare were of benefit to the clinicians as well. One example from social
media described how computer automation helps pediatricians focus on the individual
and the personalized needs of each patient.
Devices were also supportive in emergency situations. One example of this
described in social media is the development of a communication book designed for first
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responders that is valuable when a person cannot verbalize how they feel. It is evident
from the posts on social media that devices help improve symptoms and provide
important ways to communicate in general and in emergency situations. The use of such
devices support a child’s education, medical care, and monitoring of patient’s needs
related to personalized medicine. Devices bridge the gap between treatment and
symptoms by making the symptoms more apparent through day to day records and
allowing treatment responses to be monitored more easily.
Symptoms
In this study, “symptoms” included a wide range of physical or mental
appearance, reaction, and diagnosed diseases or disorders that are apparent in individuals
who also have a self-reported diagnosis of autism. The symptoms in the data were
defined in both lay and medical terms and with or without supportive laboratory results,
demographic or family history information. From social media, 692 of 1930 hits were
coded under “symptoms”, which were further divided into sub-categories.
Table 3.5
Sub-Categories of Symptoms
Sub-Categories
Behaviors
Gastrointestinal
Communication
Emotion
Allergies
Senses
Infection
Mental processes
Feeding Problems
Pain
Nervous System

Number of References Coded
534
482
329
179
168
142
132
130
105
97
97

94

Sleep
Laboratory Levels
Immune System
Skin
Respiratory
Delayed Development
Genetics
Nutritional Deficiency
Vision
Ear Nose Head
Inflammation
Ambulation
Adverse Reactions
Height and Weight
Muscles
Relationships
Potty Training
Fatigue
Regression
Detoxification
Circulation
Personality
Methylation
Limbs and Joints
Renal Function
Birth
Cardiac
Dental
Progression with Age
Jaundice
Failure to Thrive
Bone
Level of Care
Discipline
CFS/Fibromyalgia
Cancer
Reproductive Organs
Death
Frequency of Illness
Liver

86
80
71
62
59
48
45
37
30
29
29
29
25
24
23
20
19
18
17
15
15
13
13
12
12
11
10
8
7
6
6
5
4
4
3
3
3
3
2
1

Table 3.5 Sub-Categories of Symptoms.
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Behaviors, gastrointestinal, and communication problems covered 71.1, 69.6, and
47.5% respectively, of the symptoms identified in social media. The word cloud for
symptoms specified the problems associated with autism even further.
Figure 3.14
Symptoms Word Cloud

Figure 3.14 Symptoms Word Cloud showing increased word counts of constipation, food,
diarrhea, allergies, and general problems with autism.
Food allergies (138 counts or a weighted percentage of 1.19%), constipation (122 counts
or 1.05%), diarrhea (97 counts or 0.84%), and pain (79 counts or 0.68%) were the most
frequently used words to describe symptoms. For gastrointestinal problems alone
constipation, diarrhea, and reflux were the main symptoms seen in autism patients.
Questions
The questions category included 122 of 1930 hits with 820 coded references. This
category was sub-categorized into questioning causes and links, clinicians, ethics,
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information, insurance, and interventions. Many of the questions focused on legitimacy
of treatments, safety, and sought to find information from others who have experienced
similar situations. Questions asking for definitions of autism were left unanswered by the
respondents.
Other emphasis was placed on the role that parents and caregivers should take by
questioning diagnoses and suggested intervention methods, leaving a heavy weight of
skepticism among the autistic community. It is evident from the posts that people are
seeking answers, and expectations are high for legal representatives, organizations, and
government agencies to respond. The following are paraphrased excerpts from social
media hits that express the questions being raised:
Why do we see increases in cancer, autism, and allergies but human DNA
sequences have not changed at all?
How does a parent know if their child with ASD has leaky gut syndrome?
Why, doctor, is this happening to my child?
Which risk outweighs the other: the chance that a child will be autistic from
vaccination, or the chance that a child will die from a disease that could be
prevented?
What should society do if the prevalence of ASD is not enough to get government
to fund research or programs for those with autism?
How do you deal with an autism diagnosis?
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Figure 3.15
Questions Word Cloud

Figure 3.15 Questions Word Cloud showing increased word counts of questioning
especially among children as related to autism.
Improvements
Improvements were defined as reductions in symptoms as a result of intervention.
The self-report from social media resulted in 75 of 1930 hits with 787 coded references.
Improvements were sub-categorized into allergy reduction, behavior improvements,
communication improvements, dermatological improvements, endocrine improvements,
gastrointestinal improvements, growth improvements, hearing, infections, insurance
coverage, medication, neurological, nutrition, parenting, personal care, reduced adverse
events, reduced inflammation, renal improvements, sleep patterns, toilet training. The
overall word count for improvements indicates that there are less symptoms (8 counts or
1.08%) which include behavior (7 counts or 0.95%), language or speech (14 counts or
1.9%), cognition (5 counts or 0.68%), contact (5 counts or 0.68%), eye (5 counts or
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0.68%), focus (5 counts or 0.68%), school (5 counts or 0.68%), and skills (5 counts or
0.68%).
Figure 3.16
Improvements Word Cloud

Figure 3.16 Improvements Word Cloud illustrates increased word counts of
improvements in symptoms, behavior, language, speech, and diet.
Out of the word lists of improvements, diet is counted 7 times with a weighted percentage
of 0.95%, suggesting that it has a strong relationship with improved outcomes. From the
sub-coding, neurological improvements had 41 coded references, communication 38
coded references, behavior 27 coded references, and gastrointestinal 10 coded references
of specific examples of improvements from interventions. Out of all the improvements,
no one intervention had the same effect among the individuals with autism. Positive
response to treatment was best achieved when issued on a personal level. Unfortunately,
in all cases the improvements were not seen until after much trial and error. Without
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going into symptoms and interventions which have been discussed earlier, the following
are some paraphrased examples of improvement that was commonly seen throughout
social media.
Our child is doing great and is more engaged. He/she is talking and socializing
more.
Our child has a better skin color, weighs more, is taller, and has a healthy
appetite. The ear infections and chronic diarrhea are gone, and the thyroid has
normalized. We see much improvement in his/her behavior and school work.
We have noted improvements in learning, socializing, focusing, eating habits,
productivity, awareness, speech, attention, counting, labeling, following
directions, eye contact, and understanding non-verbal communication.
Additionally, we have seen a developing interest in others, better adaptation with
change, and having a natural curiosity about the world.
We placed our child with ASD on biomedical therapy. After several months of
therapy, she/he was evaluated by a group of independent professionals who had
never met him/her before. The speech and occupational therapists could not detect
ASD in our child. When the laboratory reports came back normal the biomedical
therapist said we no longer needed their services.
When implementing a diet, one rather unique method for families to offer
treatment and show support was for the entire family to follow the nutritional plan. In
some instances, siblings also showed improvement in acting out, learning, and reduction
in their own symptoms related to a disease other than autism, such as attention deficit
disorder or allergies.
Abilities
Abilities are defined in this study as the possession of skills or talents that the
individual with autism displays. Out of 1930 hits only 18 defined specific abilities. The
most common passions focused on music (7 counts or 9.23%), math (3 counts or 3.95%),
and art (2 counts or 2.63%). Other areas of interest included sewing, dance, computers,
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science, and horses. One theme defined through the posts was developing and utilizing an
individual’s special abilities to make them self sustainable. For example, organizations
exist that assist individuals in obtaining skills, improving their lifestyle, and providing
them with future employment by taking their interests such as art to create practical
commodities.
Figure 3.17
Abilities Word Cloud

Figure 3.17 Abilities Word Cloud shows the largest word counts were skills, math,
music, art, genius, and love.
Statistical Analysis
Cluster analysis was performed in NVivo to group together nodes based on words
in common. All nodes were selected and clustered by word similarity using a Pearson
correlation coefficient similarity metric. A Pearson correlation close to -1 indicates the
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items are not similar, and a Pearson correlation close to +1 shows the items are more
similar to each other. The following is a diagram of nodes clustered by word similarity:
Figure 3.18
Nodes Clustered by Word Similarity

Figure 3.18 Nodes Clustered by Word Similarity produced by QSR NVivo 10.
Table 3.6
Pearson Correlation Between Nodes
Node A

Node B

Questions
Proposed Links
Questions
Lack Deficit Need
Proposed Links
Questions
Questions
Lack Deficit Need
Questions
No Link to Autism
Feelings

Proposed Links
No Link to Autism
Lack Deficit Need
Feelings
Lack Deficit Need
No Link to Autism
Feelings
Intervention
Intervention
Lack Deficit Need
Coping

Pearson correlation
coefficient
0.8185
0.8120
0.7532
0.7121
0.7001
0.6958
0.6635
0.6238
0.6057
0.5991
0.5931
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Lack Deficit Need
Proposed Links
Questions
Feelings
Proposed Links
Proposed Links
Lack Deficit Need
Proposed Links
Intervention
No Link to Autism
Questions
No Link to Autism
Questions
Siblings
Siblings
Feelings
Siblings
Intervention
Proposed Links
Lack Deficit Need
Coping
Mechanisms
No Link to Autism
Family History
Intervention
Symptoms
Symptoms
Siblings
Symptoms
Intervention
Siblings
Proposed Links
Questions
Symptoms
Lack Deficit Need
No Link to Autism
Symptoms
Symptoms
Intervention
Symptoms
No Link to Autism

Mechanisms
Consequences
Feelings
Consequences
Consequences
Consequences
Intervention
Coping
Mechanisms
Pathology
Feelings
Consequences
Family History
Feelings
Coping
Mechanisms
Lack Deficit Need
Questions
Family History
Proposed Links
Consequences
Family History
Family History
Consequences
Intervention
Consequences
Coping
Mechanisms
Questions
Proposed Links
Feelings
Lack Deficit Need
Improvements
No Link to Autism
Coping
Mechanisms
Pathology
Intervention
Improvements
Family History
Feelings
Family History
Family History
Improvements
Coping

0.5693
0.5630
0.5581
0.5556
0.5523
0.5402
0.5357
0.5169
0.5154
0.4890
0.4825
0.4825
0.4768
0.4764
0.4754
0.4731
0.4645
0.4631
0.4596
0.4489
0.4375
0.4343
0.4213
0.4195
0.4152
0.4135
0.4123
0.3997
0.3978
0.3952
0.3952
0.3918
0.3912
0.3793
0.3728
0.3706
0.3694
0.3636
0.3567
0.3500
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Siblings
Age at Onset
Siblings
Questions
Pathology
Siblings
Family History
Proposed Links
Pathology
Symptoms
Symptoms
Improvements
Siblings
Pathology
Siblings
Symptoms
Pathology
Pathology
Symptoms
Improvements
Lack Deficit Need
Pathology
Siblings
No Link to Autism
Improvements
Proposed Links
Symptoms
Family History
Consequences
Siblings
Siblings
Questions
Improvements
Improvements
Symptoms
Feelings
Pathology
Intervention
Pathology
No Link to Autism

Mechanisms
Consequences
Age at Diagnosis
Intervention
Improvements
No Link to Autism
Family History
Coping
Mechanisms
Improvements
Lack Deficit Need
Consequences
Pathology
Feelings
Age at Onset
Consequences
Coping
Mechanisms
Age at Onset
Feelings
Intervention
Coping
Mechanisms
Consequences
Age at Onset
Family History
Age at Diagnosis
Improvements
Family History
Age at Onset
No Link to Autism
Age at Onset
Age at Onset
Pathology
Improvements
Age at Onset
Coping
Mechanisms
Age at Onset
Siblings
Age at Onset
Coping
Mechanisms
Age at Onset
Improvements
Age at Onset

0.3490
0.3473
0.3446
0.3374
0.3355
0.3340
0.3300
0.3279
0.3261
0.3201
0.3159
0.3136
0.3129
0.3050
0.3045
0.2945
0.2906
0.2893
0.2879
0.2803
0.2753
0.2723
0.2685
0.2571
0.2495
0.2445
0.2444
0.2378
0.2359
0.2298
0.2284
0.2227
0.2173
0.2168
0.2156
0.2086
0.2028
0.1985
0.1781
0.1713
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Coping
Mechanisms
Pathology
Lack Deficit Need
Questions
Family History
Proposed Links
Consequences
Feelings
Symptoms
Coping
Mechanisms
Intervention
No Link to Autism
Improvements
Symptoms
Media Provider
Special Abilities
Special Abilities
Special Abilities
Pathology
Special Abilities
Special Abilities
Special Abilities
Media Provider
Special Abilities
Special Abilities
Special Abilities
Special Abilities
Special Abilities
Special Abilities
Media Provider
Media Provider
Siblings
Media Provider
No Link to Autism
Special Abilities
Media Provider
Proposed Links
Pathology
Media Provider
Questions
Special Abilities
Media Provider

Age at Onset

0.1512

Age at Onset
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Age at Diagnosis

0.1503
0.1393
0.1151
0.1117
0.0978
0.0937
0.0902
0.0873
0.0858

Age at Diagnosis
Age at Diagnosis
Age at Diagnosis
Special Abilities
Coping
Mechanisms
Improvements
Intervention
Coping
Mechanisms
Age at Diagnosis
Feelings
Age at Onset
Consequences
Feelings
Family History
Pathology
Lack Deficit Need
No Link to Autism
Questions
Proposed Links
Intervention
Age at Diagnosis
Media Provider
Lack Deficit Need
Media Provider
Media Provider
Age at Onset
Media Provider
Media Provider
Improvements
Media Provider
Age at Diagnosis
Consequences

0.0835
0.0767
0.0732
0.0669
0.0577
0.0554
0.0488
0.0416
0.0345
0.0272
0.0268
0.0262
0.0196
0.0090
0.0079
0.0070
0.0059
0.0011
0.0007
-0.0010
-0.0017
-0.0020
-0.0021
-0.0021
-0.0021
-0.0031
-0.0032
-0.0039
-0.0039
-0.0045
-0.0047
-0.0053
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Media Provider
Special Abilities
Symptoms

Family History
Siblings
Media Provider

-0.0055
-0.0056
-0.0065

Table 3.6 Pearson Correlation between Nodes depicted as decreasing Pearson Coefficient
values.
Cluster analysis between sub-categories of questions and proposed links indicates
a high positive correlation between questioning causes and links and proposed links
(r=0.8572), proposed links and no link to autism (r= 0.811967), and questions and lack
deficit need (r= 0.7532).
Discussion
Analysis of social media entries for autism identified patterns and themes related
to GI symptoms. A pattern of symptoms leading to a diagnosis of autism included
infection at a young age, appearance of altered bowel function (e.g. constipation,
diarrhea), increased behavioral problems, and diagnosis of ASD at least a year or two
after onset. From the data, onset appears after birth and before 12 months of age.
However, autism is often not diagnosed until two or three years of age which leads to
frustration and skepticism for the current healthcare system. A need for early diagnostic
testing is seen as desirable by parents, caretakers, and clinicians as long as it is effective
and is accompanied by financial assistance. Types of financial assistance were identified
in the data set as insurance, reimbursements, or tax deduction. Early diagnostics of
particular interest, from the data, included tests that do not directly diagnose autism as a
disease, such as pharmacogenetic testing and allergy testing. These tests provide direction
in intervention application and monitoring. Patterns within the data also indicate
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pathways of interest that would lead to development of such tests and earlier diagnosis of
autism.
Based on word counts and reoccurring self-reports of symptoms, the pathway
identified in the data starts with an infection before twelve months of age. Infection is
followed by or accompanied with bowel abnormalities which over time result in
behavioral changes and increased co-morbid symptoms. The diagnosis of autism follows
this progression years later.
Three major themes emerge from the data: (1) proposed links to autism; (2)
symptoms related to food allergies and GI issues; and (3) interventions. Proposed links to
autism make up the largest theme found in social media. The links offer a glimpse into
what are believed to be causative suggestions for ASD. The majority of participants in
social media search for causes and answers related to ASD. In many cases one participant
will share symptoms of ASD to either communicate with others experiencing the same
symptoms or to seek advice for successful interventions. With no specific medication to
treat ASD, parents and clinicians typically try different approaches to relieve symptoms.
In the categories of proposed links, family history, pathology, and symptoms the
gut or gastrointestinal tract is one of the most frequently used words; indicating a
relationship between the gut and autism. Dietary measures and therapy (e.g. physical,
occupational, behavioral, etc.) are the most commonly used interventions mentioned in
social media. The data suggests that with a comprehensive family history, log of
symptoms and reactions, and genetic information, a personalized treatment plan may be
applicable to ASD. It also suggests a need to study multivariate patterns of inheritance as
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related to GI disorders, autoimmune diseases, and allergies. Epigenetic and
pharmacogenetic testing is also identified beneficial in the treatment and understanding
of ASD. The extensive amount of trial and error that occurs during the treatment process
suggest that implementation of pharmacogenetic testing may improve quality of life and
lead to more direct positive outcomes.
While social media offers many perspectives on autism which may be beneficial,
it must be recognized that the software used to mine and analyze the data and the research
team are limited in their abilities. Radian6 collected a wealth of data using the parameters
identified, but it was limited in its ability to identify repeated entries or false leads in the
data series. This resulted in the research team manually coding each entry and eliminating
repeated posts and entries not related to the search criteria. Due to the size of the dataset
and extensive time required to manually code the information, inexperienced research
team members were not able to tolerate the research load along with their academic
obligations. Therefore, the analysis from only one coder may present bias in the results
and lend itself to lack of inter and intra reproducibility of the study. To reduce the effect
of researcher bias, all the coded entries were uploaded into NVivo and an auto-code was
performed based on the selected nodes. The entries were then sub-categorized and recoded if needed in NVivo. For future studies, it would be beneficial to develop a tool
compatible with Radian6 and NVivo that would tag repeated entries and perform a
secondary scan of the data for search criteria requirements. It would also be
recommended to have at least three people to code the data to ensure interrater reliability
or agreement among the results without bias.
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Several factors presented as limitations to this study which could be improved in
future research designs. First, the study lacks inter rater reproducibility due to the issues
with coder retention. Future studies should seek funding to offer incentives and hire
experienced qualitative research coders in order to prevent coders from dropping out of
the research project. Second, the search terms entered into Radian6 produced an
extensive amount of false leads which had to be removed manually. The results from
Radian6 in addition to the use of manual coding increased risks of error. The
development of syntax to identify repeated entries would reduce the number of false
leads. Also, identification of specific search terms and the way in which they are entered
into Radian6 may reduce the need for manual coding. One suggestion would be to test
combinations of search terms and entry methods over a few days to determine the best fit
model for a larger study. The data set could also be statistically analyzed using pathway
modeling to determine if certain symptoms or categories could be used to model ASD
using social media. Future studies could then focus on using social media to model other
forms of disease and interventions.
Several advantages exist for using social media data posted in the public domain.
The first advantage is that it does not remove the person who providing the information
from their typical environment. Social media preserves the data in its original context.
Posts in the public domain reduce harm due to confidentiality breaches. It is assumed that
when a person posts information in the public domain it is intended for the public to view
and interpret on an individual basis. Information posted in the public domain allows equal
access to anyone who wishes to analyze it, and it gives the research subject the
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opportunity to regulate which information they wish to share and what they do not want
to share.
Conclusions
Mining social media data provides a tool for translating experiences, symptoms,
and reactions of disease into applicable categories that may be further studied as new
pathways, interventions, or approaches to the disease. The purpose of this study was to
explore social media in order to identify patterns and themes related to autism and GI
symptoms. Eighteen categories emerged from the data set; the top three categories
yielding themes of proposed links to autism, symptoms related to food allergies and GI
issues, and interventions. The self-reported symptoms and pathology in social media
indicate a pattern of infection at a young age that leads to GI symptoms and continues to
progress, leading to layers of symptoms and eventually an autism diagnosis.
Previous studies have identified associations between constipation, behavioral
problems and ASD (Ibrahim et al., 2009; Kral et al., 2013). This study supports the
previous associations through increased word counts for GI symptoms, behavior
problems, and autism. Major complaints of GI symptoms included changes in bowel
behavior and constipation after an infection at a young age. The pathology represented by
the data of a pathogen interrupting the epithelial barrier and creating a cascade of
symptoms is suggestive of the proposed gut to brain pathway. The data shows that layers
of symptoms accumulate as well as adverse reactions to treatment leading to delayed
diagnosis.
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Social media data gives individuals with autism a voice and it provides direction
for future research and intervention. This research shows that social media data can
identify suspected pathways of disease through identification of commonly reported
symptoms, onset, and progression over time. Social media provides an excellent
opportunity for participants to log experiences of disease over time and record treatment
responses. Examples shared through personal experiences can benefit families to
recognize symptoms and successful treatment options. Social media gives individuals and
families with autism a means of support and mechanism to share their experiences.
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Abstract
Zonulin is a precursor for the protein haptoglobin 2 and functions to regulate epithelial
tight junctions. Modulation of the tight junctions allows macromolecules to pass into the
blood stream, causing a disruption in homeostatic mechanisms that play important roles
in the development of immunity and disease. Symptoms related to epithelial barrier
permeation have been correlated with autoimmune diseases and cancer, but there is
reason to believe that similar gastrointestinal and neurological symptoms may be seen in
persons with autism spectrum disorder (ASD). This study aims to determine if increased
zonulin levels or haptoglobin genotypes are directly associated with ASDs among three
groups: individuals diagnosed with ASD and gastrointestinal symptoms, newborns, and
healthy controls. Results indicate a low negative correlation exists between zonulin
concentrations and the three groups in addition to the haptoglobin genotypes and the
groups. More studies are recommended to explain the presence of zonulin in 10% of ASD
individuals and 20% of newborns compared to the lack of zonulin in the control group.
Keywords: autism, zonulin, intestinal permeability, haptoglobin, newborns
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Zonulin, pre- haptogolobin 2 (pre-HP2), is a complex protein structure that
regulates epithelial tight junctions, allowing macromolecules to pass into the blood
stream causing altered immune responses (Tripathi et al., 2009; Wang et al., 2000).
Enterocytes of the small intestine release zonulin into the lumen when triggered by
bacteria, parasites, or gliadin (Fasano, 2012). Zonulin exists in two forms: an un-cleaved
form known as pre-HP2 that binds to protease activated receptor 2 (PAR2) and epithelial
growth factor receptor (EGFR). The second form is cleaved by trypsin at Arg161 to form
either an -2 or ß subunit of haptoglobin (HP) that seeks to bind hemoglobin but is
unable to bind to EGFR (Fasano, 2012; Tripathi et al., 2009). Original studies indicate
that the two different forms of zonulin yield two different functions due to the folding of
the protein, with only the un-cleaved form affecting intestinal epithelial permeability
(Fasano, 2012; Tripathi et al., 2009). Current research suggests that both forms of
zonulin affect permeability, but the association between zonulin and autism spectrum
disorder (ASD) is not known (Rittirsch et al., 2013).
A literature search was conducted in PubMed using the search terms “zonulin,”
“intestinal permeability,” “pre-haptoglobin 2,” and “epithelial permeability” from 20002014. The results yielded 11060 publications. The search criteria was then refined to
include autism using the search terms “intestinal permeability AND autism,” “zonulin
AND autism,” and “pre-haptoglobin 2.” The results found 96 articles from 2000-2014.
Article titles and abstracts were screened for inclusion of individuals with ASD,
eliminating articles focused on animal studies, drug development, and emphasis on
other developmental diseases.
It is known that intestinal permeability is present in individuals with ASD.
Lactose mannitol testing by D’Eufemia et al (1996) and De Magistris et al. (2010) have
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identified intestinal permeability in ASD individuals at 43% and 36.7% respectively.
Furthermore, the correlation between zonulin levels and severity of autism is supported
by the results from Adams et al. (2011) that show children with more severe forms of
ASD are likely to have more severe gastrointestinal (GI) symptoms. Children with higher
Autism Treatment Evaluation Checklist scores had GI severity index scores greater than
3 (p=0.00002) and lower levels of total short chain fatty acids (Adams et al., 2011). A
large registry-based study of 589 individuals by Wang, Tancredi, and Thomas (2011)
reported 42% of children with ASD had GI problems including constipation and diarrhea
compared with their unaffected siblings (12%). Additionally, a more recent meta-analysis
from research studies in peer-reviewed journals shows that GI symptoms of diarrhea,
constipation, and abdominal pain are greater in children with ASD compared to children
in control groups (McElhanon, McCracken, Karpen, & Sharp, 2014).
Without measuring zonulin specifically, protein marker and genotyping
exploration in individuals with ASD has indicated significant concentration differences
in proteins related to zonulin. Of greatest interest are studies surrounding HP, a form of
zonulin cleaved by trypsin and mapped to chromosome 16 (Fasano, 2011; Fasano, 2012;
Swanwick et al., 2011; Tripathi et al., 2009). Aposhian et al., (2006) showed that HP
plasma concentration was decreased in autistic male children (29.5±7.0 SE mg/dL) in
comparison to healthy controls (91.8±14.8SE mg/dL, p=0.001). Additionally, Aposhian
et al. (2006) identified an increase in HP2-2 genotypes in males with ASD (75%)
compared to normal controls (40%). These results indicate that further testing is needed
to determine relationships between HP and zonulin concentrations in serum, as well as
relationships between protein concentrations and genotype. It may be possible that
serum concentrations of HP are decreased due to decreased cleavage of zonulin, which
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would indicate an increase in zonulin in the pre-HP2 form. Therefore, the central
hypothesis of this research project is that increases in zonulin concentrations of serum
are directly associated with ASD severity and that HP2-2 genotypes place an individual
at a higher risk for developing ASD.
Symptoms reported in ASD individuals implicate physiological mechanisms of
zonulin in the onset of the disease. Symptoms of ASD include social impairment,
communication difficulties, and repetitive and stereotyped behaviors; however,
additional symptoms have been reported of stomach pain, diarrhea, constipation, acid
reflux, vomiting, bloating, and food allergies (U.S. Department of Health and Human
Services, National Institutes of Health, 2011). A review of the literature provides a list of
diseases that show association between intestinal permeability and the zonulin pathway.
Table 4.1 summarizes a list of these physiological pathways associated with zonulin and
known disease states.
[Insert Table 4.1]
The literature identifies five physiological systems that are disrupted due to increased
epithelial permeability: GI, Neurological, Oncology, Endocrine, and Respiratory
Systems. Diseases associated with increased levels of zonulin have been suggested to be
auto-immune, but there is reason to believe that symptoms related to increased zonulin
levels may be seen in other diseases not yet classified as such. This dissertation research
broadens the investigation to look at relationships between ASD, HP genotypes, and
quantitative zonulin levels through the following aims:
1.

Determine if zonulin levels in plasma obtained from individuals diagnosed with
an ASD (Group 1) or newborns (Group 2) are different from zonulin levels in
controls of healthy individuals matched by age and/ or gender (Group 3).
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2.

Examine relationships between HP2 genotypes and increased zonulin
levels in individuals with ASD (Group 1) or newborns (Group 2)
compared to healthy controls matched by age and/or gender (Group 3).

3. Determine if zonulin levels are good predictors between ASD and healthy control
groups.
Methodology

A non-experimental cohort comparison design of banked, convenience plasma
sample and matching genomic deoxyribonucleic acid (gDNA) sample from the
Greenwood Genetic Center was used in this dissertation study. Enrollment consisted of
three groups: Group 1- individuals ages 6-15 years with ASD (n=10), Group 2- newborns
(n=10), and Group 3- healthy gender and age matched controls to the autism group
(n=10). The number of samples collected for the study was based on the Clinical
Laboratory Improvement Amendments 88’ standards for clinical validation studies and
the volume of samples obtained by the Greenwood Genetic Center on an annual basis. A
minimum of 200uL of banked plasma and matching 20uL of gDNA was available for
each group. Each sample was previously characterized through medical history and
genetic testing to confirm the diagnosis of ASD. The healthy controls were also obtained
from the Greenwood Genetic Center collection. These healthy controls were previously
established as negative for ASD through medical history and genetic testing. All samples
and data were identified only by laboratory accession numbers.
Inclusion criterion for diagnosed ASD individuals included a confirmed diagnosis
of ASD as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV
(DSM-IV) criteria (American Psychiatric Association, 2013). Although the DSM has been
updated to version V, the banked samples were collected under the DSM-IV criteria and
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were measured by Autism Rating Scales developed under the same DSM criteria. Autism
Rating Scales were not specified due to the lack of standardization across the field. The
autism rating scales could include any one of twelve scales available, in order to measure
mental health symptoms, measure progress of interventions, and establish methods of
communication (Massachusetts General Hospital, 2010). Exclusion criterion for groups 1
and 2 included type 1 diabetes, multiple sclerosis, celiac disease, and rheumatoid
arthritis. This project was granted approval by the Clemson University Institutional
Review Board under exempt status.
All samples were received at the Clemson University Healthcare Genetics
laboratory. Upon receipt, the tubes were logged into a sample accession database.
Plasma and gDNA received did not have any subject identifiers and were only labeled
with a laboratory accession number, date of receipt, and laboratory technician initials.
Information accompanying each sample was labeled with only laboratory accession
numbers which link it to the sample received with no subject identifiers. The
accompanying information included ethnicity, gender, and presence/absence of autism
spectrum disorder from medical records. The samples were analyzed upon receipt.
Design for Zonulin Measurements
Research shows that intestinal permeability is present in ASD and that it is linked
with severity of ASD (Adams et al., 2011). Intestinal permeability is defined as the
capacity by which substances can penetrate the epithelial surfaces of the intestine
(Montalto et al., 1997). Two theories have been developed to explain the permeation
routes: transcellular permeation through small pores and paracellular permeation
through channels. This dissertation research focuses on the paracellular route by which
substances travel through the tight junctions. In order to objectively measure intestinal
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permeability, the first aim of this project targets the product of the mechanism that
regulates intestinal permeability by quantifying zonulin in the plasma. Plasma zonulin
levels in individuals with ASD have not been documented in the literature. The first aim
was developed to answer the following questions: 1) what are the levels of plasma
zonulin levels among the ASD population in comparison to normal healthy controls? 2)
Is there a difference in plasma zonulin levels between ASD individuals with GI symptoms
and without GI symptoms?
The working hypothesis is that increased zonulin levels in plasma are directly
and significantly associated with the presence of ASD, and higher levels of plasma
zonulin are specifically related to GI symptoms. In order to test this hypothesis, zonulin
levels were quantified using an enzyme-linked immunosorbent assay (ELISA) from
MyBioSource. This assay determined zonulin levels in plasma by measuring color
changes that result from a series of steps.
First, a reaction plate was coated with polyclonal anti-zonulin antibodies and
samples were added that were mixed with biotinylated zonulin tracer. Each sample was
run in duplicate. Free target antigens in the samples competed with the biotinylated
zonulin to bind to antibodies on the plate. Then streptavidin-labeled peroxidase antibody
bound to the zonulin tracer, tetramethylbenzidine was added and the enzyme activity
was stopped, yielding a color change. Absorbance readings were analyzed at 450nm and
540nm using a Tecan Infinite M200 absorbance plate reader.
Design for Haptoglobin Genotyping
One study has determined HP2-2 phenotypes are associated with ASD in males
(Aposhian et al., 2006). HP is a protein coding gene involved in hemoglobin binding and
catalytic activity. Genotyping can be used to determine the type of inherited alleles which
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are then suggested to predict phenotype. HP genotyping- although used to predict
increased risk of type 2 diabetes, sickle cell disease, vascular diseases, and cancers- is not
commonly tested for in individuals with ASD (Cahill et al., 2013; Haas et al., 2011;
Mandato et al., 2012; Purushothaman et al., 2012; Santos et al., 2011; Shi et al., 2012;
Speeckaert et al., 2011; Speeckaert et al., 2012). DNA testing was not done because no
studies have indicated a clinically relevant use for HP genotyping in relation to ASD.
Since zonulin is pre-haptoglobin2 and it occurs in two forms, it seems genetic testing
would be beneficial to determine the statistical relationship of each form with ASD.
The objective of specific aim two targets how genetics place an individual at
greater risk to acquire ASD. Specific aim two was developed to answer the following
questions: 1) Do genotypes of HP significantly differ between the ASD population in
comparison to normal healthy controls? 2) Does a specific HP genotype place one at a
higher risk of acquiring ASD? 3) How do plasma zonulin levels and HP genotype
uniquely contribute to ASD?
It was postulated that HP2-2 genotypes would be significantly more abundant in
individuals with ASD compared to healthy controls, and would place individuals with a
HP2-2 genotype at a higher risk of acquiring ASD. This hypothesis was tested by
genotyping HP from gDNA using real-time polymerase chain reaction (PCR).
Preliminary studies were conducted to develop and validate a HP assay to target three
common genotypes of HP: HP1-1, HP1-2, and HP2-2. Primers and probes were designed
using HP sequences AC004682 and M69197 obtained from the National Center for
Biotechnology Information nucleotide database. The probe designs target HP1 and HP2
using proprietary rapid probe technology courtesy of Co-Diagnostics for research
purposes. Probes and primers were synthesized by Integrated DNA Technologies.
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[Insert Table 4.2]
The preliminary validation indicates that the HP assay is able to detect presence or
absence of HP1, HP2, and HP1/2 genotypes with no cross reactivity using a minimum
input of 1ng gDNA. Detection limit analysis and reproducibility was determined from
dilutions at 200fM, 20fM, 2fM, 0.2fM, and 0.02fM of each HP synthetic control in
duplicate reactions. The estimated reproducibility between runs for HP1 targets is 0.855,
with a 95% confidence interval (0.474, 0.982) and for HP2 targets is .990, with a 95%
confidence interval (0.953, 0.999). Estimating reproducibility within a run, for HP1 the
ICC = 0.984, with a 95% confidence interval (0.889, 0.998) and for HP2 the ICC = 0
.990, with a 95% confidence interval (0.929, 0.999). T-tests were used to analyze the
cycle threshold values between single plex and multiplex assay using a significance value
of p< .05. The t-tests identified no significant differences in cycle thresholds between
single plex and multiplex assays, indicating that the plexing of primers and probes
together does not significantly affect the cycle threshold detection.

[Insert Figure 4.1 and Figure 4.2]
The multiplexed HP genotyping assay was performed on a CFX96 Real-time System
using reagents acquired from Bio-Rad Laboratories (Hercules, California). Each gDNA
sample was run in duplicate in a 20-uL reaction containing 10uL Sso Advanced
Universal Probes Supermix (Bio-Rad) and 1-100ng of DNA. The optimal thermal cycling
conditions included an initial denaturation step at 95˚C for 2 minutes followed by 40
cycles of denaturation at 95˚C for 30 seconds and annealing and extension at 59˚C for
30 seconds. Given that the positive controls indicate a growth curve before cycle 40 and
the negative controls indicate no growth curve, samples indicating a growth curve
between cycles 10 and 40 will be positive for the respective haptoglobin genotype. A
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growth curve in the FAM channel indicates HP1 allele, a growth curve only in the TET
channel only indicates HP2 allele, and those showing growth curves for both FAM and
TET are heterozygous for HP1/2 alleles. If the positive control shows no growth curve or
the negative control shows a growth curve, the results are invalid and the test should be
repeated using new controls.
Results
Several forms of statistical analysis were used to interpret the data. ELISA curve
fit was performed using CurveExpert Professional version 2.0. All other analyses were
performed using the Statistical Package for the Social Sciences (SPSS) version 21.0 (IBM
Corporation, Released 2012). For each analysis, the categorical variables were dummy
coded and then all variables were examined for outliers, missing values, normal
distribution, and homogeneity. For specific aim one, a correlation analysis was
performed between zonulin and the three groups. The results indicate a non-significant
low positive correlation exists between plasma zonulin concentrations and the three
groups (r= 0.206, p= 0.275), and a non-significant low negative correlation between
haptoglobin genotypes and the three groups (r= -0.164, p= 0.387). The same type of
analysis was used for specific aim two to determine the relationship between zonulin
levels and haptoglobin genotypes. Very little to no correlation was found between
zonulin and haptoglobin genotypes (r= 0.046, p= 0.808). In this case, the null
hypothesis is accepted that there is no relationship between zonulin and sample groups,
there is no relationship between haptoglobin genotype and sample groups, and there is
no relationship between zonulin levels and HP genotypes.
A one-way ANOVA was used to test for differences in zonulin levels between the
groups. The significance level of p< .05 was used for the ANOVA. The results show no
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significant differences in the means between the three groups, F (2, 27) = 0.883, p =
0.425. Table 4.3 shows the mean zonulin levels among groups of children with ASD,
newborns, and healthy controls.
[Insert Table 4.3]
Once again the null hypothesis is accepted that there are no differences in zonulin levels
among the three groups.
A binary logistic regression with a significance level of p = 0.05 was run to
determine specific aim three. A test of the model was not statistically significant from the
constant, indicating that zonulin is not a reliable predictor between groups with autism
and healthy controls (chi square = 1.176, p = 0.278 with df = 1).
Finally, Pearson’s chi square analysis was performed to determine the
relationships between the categorical data. Chi square tests were run between groups
and each of the variables including HP genotype and zonulin level (dichotomously coded
high, medium, low, very low, or zero). Statistical significance of < .05 was used for each
chi square test. The number of subjects within each group as a function of zonulin level is
shown in figure 5.2. Zonulin levels were identifiable in 20% of autism individuals (at low
levels of 2.5450 and4.9280 ng/mL), 20% of newborns (at high levels of 75.2014 and very
low levels of 0.2710ng/mL), and 50.0% of normal controls (at very low levels between
0.0060-0.9981 ng/mL. The assumptions for Pearson Chi-Square were violated with 75%
having an expected count less than 5 so the likelihood ratio values were used. The
association between zonulin levels and the three groups were significant, X2 Likelihood
Ratio (6, N=30) = 15.277, p = 0.018. Newborns were more likely to have high levels of
zonulin than the other groups, autism groups were more likely to have low levels of
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zonulin than other groups, and controls were more likely to have lower levels of zonulin
than autism or newborn groups.
[Insert Figure 4.3]
The number of subjects within each group as a function of haptoglobin genotype
is shown in figure 4.4. Heterozygous alleles of haptoglobin were present in 100% of
individuals with autism, 90% of newborns, and 90% of healthy controls. The other 10%
of newborns and 10% of controls were homozygous for haptoglobin 1 alleles. The
assumptions for Pearson Chi-Square were violated with 50% having an expected count
less than 5 so the likelihood ratio values were used. The association between haptoglobin
genotype and the three groups were not significant, X2 Likelihood Ratio (2, N=30) =
1.692, p = 0.429.

[Insert Figure 4.4]
Discussion & Conclusion
Even though no statistically significant levels were reached from this study, the
absence and low levels of zonulin in healthy controls and medium to high levels of
zonulin in individuals with ASD and newborns suggest the possibility of clinical
significance. The zonulin levels that were present within each sample group raise
suspicion that clinical differences in zonulin levels exist when excess zonulin does not
clear the system shortly after birth. The high levels of zonulin in newborns compared to
the low levels in controls suggest that zonulin decreases over time after birth except in
the presence of disease. It is unclear whether increased levels of zonulin at young ages
cause disease. These suspicions could only be objectively tested with a larger number of
samples for each group. More research is recommended to investigate the role of
intestinal permeability and ASD. It is evident from previous research that GI symptoms
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are more common among individuals with ASD than normal controls (Adams et al.,
2011; Buie et al., 2010). One of the major factors influencing the outcome of this
dissertation research project was the small sample size and limited funds. With more
funding, a larger sample size could be obtained lending itself to a better statistical
outcome. Other potential limiting factors include reversal mechanisms of the gut which
function to create a barrier to potential pathogens, tissue specificity of zonulin, or
unknown variables that are not accounted for in this study (Fasano, 2011). Reversal of
zonulin in gut function has been documented in cases of celiac disease (Drago et al.,
2006). Studies suggest that intestinal permeability increases and then returns to baseline
over time, but the baseline levels between disease – ASD included- and normal controls
remain significantly different (Drago et al., 2006; Tripathi et al., 2009). Since ASD
studies documenting dietary interventions of diet indicate a plateau effect, this reversal
mechanism has a potential to interfere with direct linear relationships between zonulin
and ASD (Whiteley et al., 2010).
A study by Aposhian et al. (2006) indicates a connection between HP2-2
genotypes and ASD, and preliminary data from social media suggests relationships exist
between GI symptoms and ASD. However, in this study there was no significant
differentiation in HP genotype among the three groups. Differences related to ethnicity
were unachievable due to the availability of samples. The results from this study
contrasted greatly from previous findings by other researchers, in that a majority of
samples from this study are heterozygous for HP. The differences in HP genotype related
to ASD may be the result of gender or the presence of gastrointestinal symptoms. The
results related to ethnicity from this study are inconclusive due to small numbers of
ethnic groups. A larger study would need to be repeated to provide better statistical
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evidence of using HP genotype to predict risk of ASD and to define the role that ethnicity
plays in HP genotyping and disease. For example, future studies might include more
than just HP genotype but other genotypes associated with ASD and/or zonulin.
Finally, the unknown always presents a possible problem in research but it can
only be dealt with upon discovery. In this case, zonulin has not been found to be a useful
predictor of ASD, but the results are of significant interest in directing future research.
Other mechanisms in the zonulin pathway may also be of interest using genome wide
association or methylation studies among ASD. The ground work has been established
that intestinal permeability is present in ASD and that GI symptoms are linked to
severity, but there may be unknown factors that account for these relationships that are
not currently known. For this reason, it is suggested that the study be replicated with
increased sample numbers to detect zonulin levels within subgroups of ASD specific only
to GI disorders or other potential mechanisms that are shared between intestinal
permeability and ASD.
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Tables
Table 4.1
Diseases Associated with Zonulin
Physiological
Category
Gastrointestinal
System
Respiratory
System

Nephrological
System
Neurological
System

Endocrine System

Infectious
Diseases

Cancers

Disease

References

Celiac

Duerksen et al., 2010; Fasano et al.,
2000; Tripathi et al., 2009; Wang et al.,
2000
Duerksen et al., 2010
Fasano , 2008
Matthay et al., 2003
Matthay et al., 2003

Colitis
Crohn’s Disease
Acute Lung Injury
Acute Respiratory
Distress Syndrome
Asthma
Chronic Kidney
Disease
Schizophrenia
Alzheimers
Multiple Sclerosis
Obesity
Diabetes Mellitus
Type 2
Type 1 Diabetes
Systemic Lupus
Erythematosus
HIV
HCV
Sepsis
Breast Cancer
Glioblastoma
Lung squamous
carcinoma
Pancreatic carcinoma

Fasano, 2011
Kelly et al., 2009
Paterson et al., 2007
Liu et al., 2012
Fasano, 2011
Moreno-Navarrete et al., 2012; Zak-

Gołąb et al., 2013
Jayashree et al., 2014; Moreno-Navarrete
et al., 2012
Sapone et al., 2006; Watts et al., 2005
Pavon et al., 2006
Liu et al., 2012
Fasano, 2011
Klaus et al., 2013
Russo et al., 2013
Skardelly et al., 2009
Fasano, 2011
Fasano, 2011
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Tables (continued)
Table 4.2
Haptoglobin Primer & Probe Design
ID

Tm (ºC)

Sequences 5’-3’

HP1 Forward
Primer
HP1 Reverse
Primer
HP2 Forward
Primer
HP2 Reverse
Primer
HP1 Probe

59.3

gcaagctcccctcatttct

59.7

actcaggcaatgatgtcacg

60.5

aatctgagctccagccagtg

59.1

agctgctctgcacatcaatc

63.3

[FAM] atggtcctgaaagcccagaggtcgaaggacca [DABCYL]

HP2 Probe

64.7

[TET] tagcccctagccctttcaatgggct [DABCYL]

Table 4.3
Descriptive Statistics
Dependent Variable: zonulin
Group ID

Mean

Std.
Deviation

N

Autism

0.7523

1.6786

10

Controls

0.2122

0.3274

10

Newborn

7.5472

23.7714

10

Total

2.8372

13.7041

30

133

Table legends
Table 4.1 Diseases Associated with Zonulin. A literature review search in PubMed
acquired in August, 2013 identified the systems and diseases associated with zonulin.
Table 4.2 Haptoglobin primer and probe design. The design illustrates the proprietary
hybridization probe design based on Co-Diagnostic’s rapid probe technology. The
fluorophores were selected to use in a complimentary fashion for multiplexing capability.
Table 4.3 Descriptive Statistics. This chart shows the mean zonulin levels among the
groups of individuals with ASD, newborns, and healthy controls.
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Figures

Figure 4.1
Real-time PCR of HP1 Dilution Series

Figure 4.2 Real-time PCR of HP2 Dilution Series
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Figures (continued)
Figure 4.3

Figure 4.4
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Figure Legends
Figure 4.1 Real-time PCR of HP1 Dilution Series. The plot shows the cycle thresholds and
growth curves for a HP1 control serial dilution at 200fM, 20fM, 2fM, 0.2fM, and .02fM
concentrations.
Figure 4.2 Real-time PCR of HP2 Dilution Series. The plot shows the cycle thresholds
and growth curves for a HP2 control serial dilution at 200fM, 20fM, 2fM, 0.2fM, and
.02fM concentrations.
Figure 4.3 Effect of Zonulin on Group Identification. The graph shows the zonulin levels
among the number of subjects within each group.
Figure 4.4 Effect of Haptoglobin Genotype on Group Identification. The graph shows the
haptoglobin genotype among the number of subjects within each group.
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CHAPTER V
CONCLUSION
Translational research brings knowledge from multiple disciplines together and sets that
knowledge into action within clinical practice. Using the knowledge to action framework, this
project has moved through multiple phases from translation to research. As this research clearly
indicates, this translational process is littered with much trial and error moving continuously from
the translation phase back to the research phase. It almost seems as if research and translation is a
continuous cycle with only an occasional, random institutionalization output. None-the-less,
without continuous research as demonstrated through the previous four chapters lives would not
be saved from disease and healthcare would not progress. Chapter I summarized how the research
within this project fits within the knowledge to action framework. The chapter provided
conclusions from each experiment and future directions to push forward toward
institutionalization.
In chapter I, the knowledge to action framework was introduced along with brief
summaries of how each of the subsequent research chapters would fit within the framework. This
chapter defined translation as the process by which an application is moved from the development
phase into action within the clinical setting. It introduced Chapter II, an article that reviews the
current status of zonulin associated intestinal permeability and ASD and indicates a gap in early
diagnostic testing that can be developed for clinical use.
Chapter III explored social media for themes and patterns of autism and GI symptoms
collected using Radian6. It was anticipated that the themes presented first hand by individuals
with autism, care takers, and friends or family through social media can implicate relationships
and themes of disease that stimulate the need for further research. Three major themes were
identified: 1) proposed links to autism, 2) symptoms related to food allergies and GI
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issues, and 3) interventions. The pathways of disease present through social may be
further analyzed to create pathway models for ASD and other diseases. Additionally, the
information obtained through social media data may be used to create novel interventions. In this
case, it is projected that preliminary exploration of ASD symptoms reported in social media
indicate large numbers of GI dysfunction, GI symptoms, early onset of bacterial infection and
food allergies. The research extended this investigation to look at quantitative relationships
between ASD, HP genotypes, and quantitative zonulin levels.
Although ELISA testing has been used as a “gold standard” method of testing for many
diseases, this research suggested that molecular testing may prove to be a more sensitive, specific,
and rapid way of testing for disease at an earlier stage. Real-time PCR testing can detect the
presence of virus at early onset even before symptoms develop. The results from zonulin and
haptoglobin testing for ASD showed no significant relationship between zonulin levels,
haptoglobin genotype, and the presence of ASD. However, the presence of GI symptoms and the
extremely high zonulin (>40ng/mL) in 10% of ASD and presence of zonulin at 2-5ng/mL in
newborns compared to no zonulin detection in healthy controls suggest more research is needed.
A larger sample population combined with more medical history and genome sequencing may
provide answers needed to explain the mechanisms of zonulin and etiology of ASD. The
qualitative social media data mining of ASD and GI symptoms using Radian6 supported the need
for more genetic testing, specifically related to epigenetic and pharmacogenetic testing. The
qualitative data indicated that genetic testing could lead toward more personalized treatment
options whether or not it could be used for early diagnosis.
The need to reduce trial and error that occurs during the treatment process was a repeated
theme throughout each chapter under no boundaries of disease type. In each case, genetic testing
and a comprehensive patient history were the common factors with the ability to reduce trial and
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error while maintaining quality of life. Of interest was the ability of qualitative data mining of
social media to come to such conclusion regarding genetic testing and the ability to suggest a
model of disease pathology that may be tested experimentally. A follow up study using the
qualitative data would be to create a pathway model designed to use data collected from social
media to model any disease pathway. All research suggests the need for a comprehensive family
history and log of symptoms and reactions to obtain an early diagnosis. Like many diseases, ASD
show patterns of early onset symptoms that may or may not be readily visible to the human eye.
Therefore, effective early diagnostic testing is desirable to detect the presence of disease or
specific symptoms with accompanying recommendations for treatment. Pharmacogenetic testing
presents a viable option for diseases that do not currently have a confirmatory diagnostic test in
that it can help determine treatment options based on the body’s capacity to metabolize specific
substances. Conclusively early diagnostic testing is desirable as long as the cost for such testing is
minimal.
Testing for zonulin presents a new innovative method of detecting intestinal permeability.
To date all of the tests associating intestinal permeability with ASD have been measured using
LM tests (De Magistris et al., 2010; D’Eufemia et al., 1996). The LM test involves oral
administration of a solution of mannitol and lactulose with subsequent assessment of small
intestine absorption measured by a six hour urine collection (Cooper, 1984). For children, LM
testing has been used to determine allergies and intestinal permeability, but the methods of oral
administration and collection are very difficult to obtain due to the use of diapers and inability of
children to anticipate the need for urination and bowel movements. Although this research
detected no significant relationship between zonulin levels and ASD, it does not discount the use
of zonulin ELISA tests as a replacement for LM testing. The research here presents the use of
zonulin ELISA testing and HP genotyping as novel early diagnostic method for intestinal
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permeability. The implementation of these methodologies represents a paradigm shift in the use
of proteomic and genomic diagnostic testing from clinical diagnosis to pre-symptomatic testing.
Early diagnostic testing may prevent or reduce altered developmental endpoints and may
specifically define the severity of the related disease. Next steps in the development of early
diagnostic testing would be to conduct experiments to compare the use of serum zonulin testing
to LM testing to identify which is most effective and to understand their application on a global
scale. It may also be of interest to incorporate this testing of diagnostic techniques with the
current autism rating scales and treatment regimens to monitor adverse events. It is inevitable for
testing methods to remain in a cycle of research and translation. Genetic recombination events
and mutations do not stop with time they continue to produce new phenotypes; therefore, all
testing standards, even “gold standards,” need to be constantly re-evaluated to ensure they
perform at optimal efficiencies. Finally, early diagnostic tests simply measured from blood
collection could result in a rapid turn-around-time for reporting clinical results, future
development of point-of-care assays, and provide direction and significance for continuing
zonulin research.
An extension of zonulin research in relation to ASD is warranted by the differences in the
zonulin concentrations between ASD individuals (M= 0.7523, SD = 1.6786), newborns (M=
7.5472, SD = 23.7714), and healthy controls (M= 0.2122, SD = 0.3274). With a larger samples
size, it is possible that zonulin levels between groups will be significant. Future studies suggest
repeating this exact experiment with at least 30 samples per group and extending the research to
explore differences between ASD individuals with and without GI symptoms. Another aspect is
to further explore zonulin levels from birth to adulthood to see how the levels may fluctuate
related to changes in diet from nursing or formula to solid foods, and to study levels of zonulin
from birth to adulthood in relation to disease development. Of additional interest would be
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development of symptoms or disease over time in relation to the zonulin levels. Genome wide
sequencing of all of these individuals may also help understand gene interactions related to
intestinal permeability and patterns of inheritance. In addition to exploring zonulin levels,
pharmacogenetics and epigenetics of ASD should be explored.
The array of symptoms and levels of severity related to ASD make it hard for a single
intervention to work for all individuals. Pharmacogenetics and epigenetic studies of ASD provide
opportunities to understand metabolism and methylation patterns. Based on results from social
media, pharmacogenetic testing should focus on medications related to pain, neurological
conditions, and gastrointestinal symptoms. The use of pharmacogenetic testing would make
personalization of treatment an option to avoid adverse events and frustration experienced as a
result of trial and error interventions.
In conclusion, future research will have translational importance in the development of
novel early diagnostic testing for the prevention and aggressive treatment of disease. The
development of diagnostic methodologies will lead to interventions that will improve quality of
life for both the affected individuals and their care takers.
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APPENDIX A: GLOSSARY OF TERMS
TERM
Research Phase

DEFINITION

REFERENCE

The first phase within the knowledge to action

Wilson et al., 2011

framework

that

includes

discovery,

efficacy,

effectiveness, and research supporting structures.
Translation

The second phase within the knowledge to action

Phase

framework that includes translation, decisions to

Wilson et al., 2011

translate, knowledge into products, dissemination,
engagement, decisions to adopt, practice,

and

translation supporting structures.
Translation

The process of putting research into clinical practice, Wilson et al., 2011
which is not dependent on a certain method of
implementation or intervention.

Early

A method that indicates presence/absence, risk, or

Diagnostics

severity of a disease or condition prior to the
manifestation of symptoms or outside of the
traditional guidelines for diagnosis.
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APPENDIX C: PERMISSIONS FOR USE
1. Permission to use Figure Figure 1.1 NCCDPHP Knowledge to Action Framework for
Public Health:
Fri, Mar 7, 2014 at 9:14
AM

Rebecca Garcia <ragarci@g.clemson.edu>
To: kwilson@cdc.gov
Cc: Julia Eggert <jaegger@clemson.edu>
Hi,

I am writing to request permission to use the diagram of the knowledge to action framework as
printed in:
Wilson KM, Brady TJ, Lesesne C, on behalf of the NCCDPHP Work Group on Translation. An organizing
framework for translation in public health: the Knowledge to Action Framework. Prev Chronic Dis
2011;8(2):A46. http://www.cdc.gov/pcd/issues/2011/mar/10_0012.htm.
I am using the framework as a basis for my dissertation research and would like to use the figure to
help explain the framework. Please note that I have cc'd my advisor on this email. Thank you for your
time and consideration.
Thanks,
Rebecca Garcia
Healthcare Genetics Program
Clemson University
-- [The information transmitted is intended only for the person or entity to which it is addressed and may contain proprietary,
business-confidential and/or privileged material. If you are not the intended recipient of this message you are hereby notified that any
use, review, retransmission, dissemination, distribution, reproduction or any action taken in reliance upon this message is prohibited. If
you received this in error, please contact the sender and delete the material from any computer.]

Wilson, Katherine (Kathi) (CDC/OPHSS/CSELS) <kxw1@cdc.gov>
To: "ragarci@g.clemson.edu" <ragarci@g.clemson.edu>
Cc: "jaegger@clemson.edu" <jaegger@clemson.edu>

Hi, Rebecca.
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Fri, Mar 7, 2014 at 12:14
PM

Of course you can use it. The journal, Preventing Chronic Disease, and I are both federal,
which means we are in the public domain. I would appreciate you referencing the paper,
though.
Good luck. If you are so inclined to share, let me know how you used the K2A. A lot of good
people were involved in developing it and would be glad to hear about it.
Thank you.
Kathi

2. Permission to use Figure 4.1 Bacteria and Virus Alteration of Tight Junctions:
Rebecca Garcia <ragarci@g.clemson.edu>

Fri, Jun 20, 2014 at 10:50 PM

To: jguttman@sfu.ca
Hi,
I am writing to request permission to use Fig 2 from your published article "Tight junctions as targets
of infectious agents" in Biochim Biophys Acta. 2009 Apr;1788(4):832-41. doi:
10.1016/j.bbamem.2008.10.028. Epub 2008 Nov 14. I would like to incorporate the figure as an
illustration in my dissertation manuscript. I appreciate your time and consideration.
Best Regards,
Rebecca Garcia, PhD(c)
Healthcare Genetics Doctoral Program
Clemson University
-- [The information transmitted is intended only for the person or entity to which it is addressed and may contain proprietary,
business-confidential and/or privileged material. If you are not the intended recipient of this message you are hereby notified that any
use, review, retransmission, dissemination, distribution, reproduction or any action taken in reliance upon this message is prohibited. If
you received this in error, please contact the sender and delete the material from any computer.]

Sat, Jun 21, 2014 at 9:31 AM
Julian Guttman <jguttman@sfu.ca>
To: Rebecca Garcia <ragarci@g.clemson.edu>
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Hi Rebecca,
Yes, I absolutely give you permission!
Good luck on your dissertation.
Julian Guttman
[Quoted text hidden]

******************
Julian A. Guttman, PhD.
Associate Professor
CIHR New Investigator
Department of Biological Sciences Graduate Program Chair

Simon Fraser University
8888 University Drive
Department of Biological Sciences
Room B8276
Burnaby, BC V5A1S6
Tel: 778-782-4459 (Office)
778-782-8618 (Lab)
Fax: 778-782-3496
e-mail: jguttman@sfu.ca
http://www.sfu.ca/biology/faculty/guttman/

This email is confidential. It is intended only for the use of the person to whom it is addressed. Any
distribution, copying or other use by anyone else is strictly prohibited. If you have received this e-mail in error,
please destroy this e-mail.
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